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Although ovarian cancer has a low incidence rate, it remains the most deadly 
gynecologic malignancy.  Research conducted in our laboratory has led to the 
development of a novel combination therapy which combines a DNA methyl 
transferase inhibitor (DNMTi) and an ornithine decarboxylase inhibitor that together, 
alter the tumor microenvironment to inhibit ovarian tumor growth. Previous work 
demonstrated that the DNMTi, 5-Azacytidine (AZA), activates type I interferon 
signaling to increase IFNγ+ T cells and NK cells and to reduce the percentage of 
macrophages in the tumor microenvironment. To improve the efficacy of epigenetic 
therapy, we hypothesized that the addition of α-difluoromethylornithine (DFMO), an 
ornithine decarboxylase inhibitor that reduces intracellular polyamines, may further 
decrease immunosuppressive cell populations. We tested this hypothesis in the 
VEGF-β-Defensin ID8 (VDID8) model, an immunocompetent and 
immunosuppressive mouse model for ovarian cancer, and found that in vivo AZA, 
DFMO, and AZA+DFMO significantly decreased tumor burden, and increased both 
survival and recruitment of activated (IFNγ+) CD4+ T cells, CD8+ T cells, and NK 
cells compared to vehicle. Combination therapy further led to a dramatic decrease in 
immunosuppressive cells such as M2 polarized macrophages and an increase in 
tumor-killing M1 macrophages. Using a CSF1R blocking antibody, we found that 
depleting macrophages in this model reduced the efficacy of AZA+DFMO treatment, 
and resulted in fewer M1 macrophages in the tumor microenvironment. We thus 
conclude that our novel combination therapy modifies macrophage polarization in 




After establishing an important role for macrophages in the AZA+DFMO response, 
we next tested the drug combination in additional solid tumor models, including the 
p53-/- ID8 ovarian cancer model and the 2208L breast cancer model. In both tumor 
models, combination AZA+DFMO had the greatest survival benefit as observed in the 
VDID8 model; however, single agent DFMO had a pronounced benefit in survival 
compared to single agent AZA. Subsequent experiments in the VDID8 model analyzed 
macrophage subpopulations at a greater depth, assessing whether AZA and DFMO 
affected tissue resident peritoneal macrophages or led to recruitment of M1 
macrophages from secondary lymphoid tissue. DFMO alone was found to impact 
these tissue resident macrophages, polarizing them to an M1 phenotype, while AZA 
treatment had no impact on tissue resident macrophages.  
We therefore hypothesize that DFMO treatment promotes M1 macrophage 
polarization at the tissue level, while AZA treatment promotes M1 macrophages 
through a system wide interferon and anti-viral immune response. Combined AZA and 
DFMO work synergistically in the VDID8 ovarian model possibly due to the high 
vascularization, while solid tumors such as the p53-/- ID8 model and 2208L breast 
model, the benefit to combination therapy is less pronounced. In these solid tumors, 
decreased vascularization could diminish the ability of recruited immune cells to 
penetrate the tumor; however DFMO is able to impact the macrophages that are 
already present at the tissue site.  
Thesis Advisor: Dr. Cynthia A. Zahnow 





I am so thankful for all of my mentors here at Hopkins, every member of my 
thesis committee, and the Cellular and Molecular Medicine (CMM) program that 
has felt more like a family than a program during my tenure here. First and foremost 
I have to thank my mentor Dr. Cynthia Zahnow and my informal co-mentor Dr. 
Robert Casero for providing me with every opportunity to succeed.   Cindy and 
Bob together have helped mold me into the scientist I am today and I know that I 
can turn to them for advice even now, as I continue to the next stage of my career. 
I’m lucky to have had two outstanding mentors who encouraged me to follow my 
scientific instincts and interests, while also teaching me their lessons learned from 
years of experience. Without them, I would not be where I am today. I must also 
thank every member of my Thesis Committee: Dr. Fred Bunz, Dr. Zaver Bhujwalla, 
and Dr. Deborah Armstrong for all of their guidance and insight throughout my 
graduate career.  
I am incredibly grateful for my informal, immunology and teaching mentor Dr. 
Alan Scott for providing me with wonderful teaching opportunities that made me 
even more excited about immunology research. I was very lucky to have Alan to 
turn to when I got a piece of data I wanted to discuss or an experiment I thought 
might be a good idea. His career advice has led me to an incredible postdoc 
opportunity at Harvard Medical School and I truly could not be more thankful for 





All members of our bigger cancer epigenetics lab group at Hopkins—the Baylin 
lab and Casero lab—every person has been helpful, collaborative, and generous 
with both reagents and their own personal knowledge. It has been a wonderful 
work environment and has fostered some of the best science in the field. I have to 
single out our research technician in the Zahnow lab, Stephen Brown for all of his 
support. Twelve hour days in lab, countless hours of mouse work… nearly every 
single data point I collected was with Stephen’s help and I cannot express how 
grateful I am for him. 
The CMM program at Hopkins is truly very special. Our program director Dr. 
Rajini Rao, manager Colleen Graham, and administrator Leslie Lichter-Mason 
fostered an encouraging environment that is absolutely essential to success as a 
PhD student. These lovely women set the tone for our program as a whole, which 
was extremely supportive and collaborative. Me and my fellow 2015 classmates 
studied together, worked on homework sets together, and prepared for our 
qualifying exams together. Everyone in CMM is incredibly talented and I cannot 
wait to follow their careers and see where we all end up. 
Finally, and most importantly, I want to thank my family: my mom, dad, 
grandparents, brother, sister, nieces, and nephew. I’ve missed you all so much 
since moving to Baltimore. I know it was not something that anyone wanted me to 
do, but you were supportive of my decision regardless and I’m so thankful for that. 




Table of Contents 
Title Page ..............................................................................................................ii 
Abstract .................................................................................................................ii 
Acknowledgements ..............................................................................................iv 
Table of Contents ................................................................................................ vii 
List of Figures ...................................................................................................... iix 
List of Abbreviations ........................................................................................... ixv 
Background and Motivation .................................................................................. 1 
1.1 Ovarian Cancer and its tumor microenvironment .............................. 1 
1.2 DNMTis and the antiviral immune response ..................................... 2 
1.3 Polyamines as anti-inflammatory agents .......................................... 3 
1.4 TAMs as both pro- and anti-tumorigenic ........................................... 6 
Experimental protocol ......................................................................................... 10 
2.1 Animal models ................................................................................ 10 
2.1.1 VEGF-β-Defensin ID8 Ovarian Cancer Model .......................... 10 
2.1.2 p53-/- ID8 Ovarian Cancer Model ............................................. 11 
2.1.3 2208L Breast Cancer Model ..................................................... 11 
2.2 Flow Cytometry ............................................................................... 12 




Chapter 1: AZA+ DFMO activate the immune system ........................................ 14 
3.1 Introduction ..................................................................................... 14 
3.2 Methods .......................................................................................... 14 
3.3 Results ............................................................................................ 16 
3.3.1 Treatment reduces tumor burden and increases survival ......... 16 
3.3.2 AZA+DFMO has few impacts on cell cycle ............................... 26 
3.3.3 Treatment leads to increased lymphocyte populations ............. 32 
3.3.4 Addition of α-PD-1 does not provide added benefit .................. 40 
3.4 Discussion ...................................................................................... 50 
Chapter 2: AZA+DFMO alter TAMs and promote M1 polarization ...................... 52 
4.1 Introduction ..................................................................................... 52 
4.2 Methods .......................................................................................... 52 
4.3 Results ............................................................................................ 54 
4.3.1 AZA+DFMO reduce population of macrophages ...................... 54 
4.3.2 Treatment promotes M1 over M2 polarization .......................... 61 
4.3.3 Macrophage depletion diminishes AZA+DFMO efficacy .......... 70 
4.4 Discussion ...................................................................................... 87 
Chapter 3: AZA+DFMO in solid tumor models ................................................... 89 
5.1 Introduction ..................................................................................... 89 




5.3 Results ............................................................................................ 91 
5.3.1 AZA+DFMO in p53-/- ovarian cancer model ............................ 91 
5.3.2 DFMO alone reduces tumor burden in 2208L breast model ... 103 
5.3.3 DFMO activates GATA6+ peritoneal macrophages ............... 117 
5.4 Discussion .................................................................................... 126 
Conclusions and Future Directions ................................................................... 128 
6.1 Summary ...................................................................................... 128 
6.2 Future directions ........................................................................... 130 
References ....................................................................................................... 134 





List of Figures 
 
Figure 1.1: The enzyme arginase (ARG1) first catalyzes the conversion of arginine 
to ornithine, creating the substrate for ornithine decarboxylase (ODC). ....... 3 
 
Figure 1.2: L-arginine metabolism pathways..  ..................................................... 8 
 
Figure 2.1: Percent survival of p53-/- ID8 tumor in WT C57BL/6NHsd mice..  ... 11 
 
Figure 3.1: Tumor cell injection and treatment schematic..  ................................ 18 
 
Figure 3.2: Polyamine levels in cultured VDID8 cells.. ....................................... 19 
 
Figure 3.3: Polyamine levels in bulk ascites fluid from treated mice..  ................ 20 
 
Figure 3.4: Tumor burden, represented by ascites volume, 4 weeks post tumor 
injection..  ................................................................................................... 21 
 
Figure 3.5: Tumor burden, represented by ascites volume, 5 weeks post tumor 
injection..  ................................................................................................... 22 
 
Figure 3.6: Representative survival curve..  ........................................................ 23 
 
Figure 3.7: Flow cytometry plots of SSC vs. FSC demonstrating an increase in 
lymphocyte populations..  ........................................................................... 24 
 
Figure 3.8: Total lymphocyte populations in week 5 bulk ascites fluid of mice..  25 
 
Figure 3.9: Cell cycle analysis of in vitro AZA+DFMO treatment of VDID8 cells.. 
 ................................................................................................................... 28 
 
Figure 3.10: Cell cycle analysis of in vivo AZA+DFMO treatment of mice previously 
injected IP with VDID8 cells..  ..................................................................... 29 
 
Figure 3.11: Gene set enrichment analysis for DFMO, AZA, and AZA+DFMO 
treated VDID8 cells..  .................................................................................. 30 
 
Figure 3.12: Gene set enrichment analysis for GFP+ isolated tumor cells from mice 
treated with DFMO, AZA, and AZA+DFMO..  ............................................. 31 
 
Figure 3.13: Number of total T cells shown as a percent of total cells, isolated from 





Figure 3.14: Number of total NK cells shown as a percent of total cells, isolated 
from ascites fluid of mice at week 5 post tumor injection..  ......................... 34 
 
Figure 3.15: Number of total CD4+ “Helper” T cells shown as a percent of total 
cells, isolated from ascites fluid of mice at week 5 post tumor injection..  .. 35 
 
Figure 3.16: Number of total CD8+ cytotoxic T cells shown as a percent of total 
cells, isolated from ascites fluid of mice at week 5 post tumor injection..  .. 36 
 
Figure 3.17: Number of IFNγ+ CD4+ T cells, shown as a percentage of CD4+ T 
cells..  ......................................................................................................... 37 
 
Figure 3.18: Number of IFNγ+ CD8+ T cells, shown as a percentage of CD8+ T 
cells..  ......................................................................................................... 38 
 
Figure 3.19: Number of IFNγ+ NK cells, shown as a percent of NK cells..  ........ 39 
 
Figure 3.20: Number of PD-L1+ tumor cells, collected from ascites fluid of mice at 
4 weeks post tumor cell injection, shown as a percentage of tumor cells..  41 
 
Figure 3.21: Number of PD-L1+ tumor cells, collected from ascites fluid of mice at 
6 weeks post tumor cell injection, shown as a percentage of tumor cells..  42 
 
Figure 3.22: Number of PD-1+ CD4+ T cells, shown as a percentage of CD4+ T 
cells..  ......................................................................................................... 43 
 
Figure 3.23: Number of PD-1+ CD8+ T cells, shown as a percentage of CD8+ T 
cells..  ......................................................................................................... 44 
 
Figure 3.24: Treatment regimen for α-PD-1 therapy..  ........................................ 45 
 
Figure 3.25: Treatment with α-PD-1 therapy alone provided no survival benefit to 
mice..  ......................................................................................................... 46 
 
Figure 3.26: Addition of α-PD-1 to DFMO provided a slight benefit in survival to 
mice, but was not significant..  .................................................................... 47 
 
Figure 3.27: Addition of α-PD-1 to AZA provided no survival benefit to mice..  .. 48 
 
Figure 3.28: Addition of α-PD-1 to combination AZA+DFMO provided no survival 





Figure 4.1: Total non-lymphocyte cells in the tumor microenvironment, as a 
percentage of total cells collected from ascites fluid..  ................................ 56 
 
Figure 4.2: Total MDSCs in the tumor microenvironment, as a percentage of total 
cells..  ......................................................................................................... 57 
 
Figure 4.3: Total macrophages in the tumor microenvironment as a percentage of 
total cells..  ................................................................................................. 58 
 
Figure 4.4: Macrophages positive for the surface marker MHC II, and therefore 
capable of presenting antigen to CD4+ T cells..  ........................................ 59 
 
Figure 4.5: Macrophages negative for the surface marker MHC II, and therefore 
unable to present antigen to CD4+ T cells.. ............................................... 60 
 
Figure 4.6: M1 macrophages (CD206- MHC II+) in the tumor microenvironment, 
as a percentage of F4\80+ CD11b+ macrophages..  .................................. 63 
 
Figure 4.7: M2 macrophages (CD206+ MHC II-) in the tumor microenvironment, 
as a percentage of F4\80+ CD11b+ macrophages..  .................................. 64 
 
Figure 4.8: qRT-PCR for Arg1 on sorted macrophages..  ................................... 65 
 
Figure 4.9: qRT-PCR for Fizz1 on sorted macrophages..  .................................. 66 
 
Figure 4.10: qRT-PCR for iNOS2 on sorted macrophages..  .............................. 67 
 
Figure 4.11: Representative flow cytometry data shown for one mouse treated with 
combination AZA+DFMO in vivo..  ............................................................. 68 
 
Figure 4.12: Percentage of M2 macrophages (MHCII- CD206+) increase with 
tumor burden in vehicle treated mice..  ....................................................... 69 
 
Figure 4.13: Treatment regimen for α-CSF1R block antibody or IgG control 
antibody..  ................................................................................................... 72 
 
Figure 4.14: Significantly reduced macrophage population, as a percentage of total 
cells, with α-CSF1R treatment..  ................................................................. 73 
 
Figure 4.15: L Significantly increased circulating M-CSF cytokine levels in bulk 





Figure 4.16: Tumor burden represented by ascites volume in mice treated with 
AZA+DFMO in presence of CSF1R antibody or IgG control during the second 
drain..  ........................................................................................................ 75 
 
Figure 4.17: Tumor burden during the third drain (week 9 on schematic in Fig 4.11) 
demonstrating an increase in tumor burden in AZA+DFMO mice receiving 
CSF1R..  ..................................................................................................... 76 
 
Figure 4.18: Survival curve of AZA + DFMO treated mice receiving CSF1R 
antibody..  ................................................................................................... 77 
 
Figure 4.19: M1 macrophages (CD206- MHC II+) analyzed via flow cytometry at 
the second drain..  ...................................................................................... 78 
 
Figure 4.20: M2 macrophages (CD206+ MHC II-) analyzed via flow cytometry at 
the second drain..  ...................................................................................... 79 
 
Figure 4.21: M2 macrophages (CD206+ MHC II-) analyzed via flow cytometry at 
the first drain in mock mice receiving either α-CSF1R or IgG control..  ...... 80 
 
Figure 4.22: Number of IFNγ+ CD4+ T cells, shown as a percentage of CD4+ T 
cells during the second drain..  ................................................................... 81 
 
Figure 4.23: Number of IFNγ+ CD8+ T cells, shown as a percentage of CD8+ T 
cells during the second drain..  ................................................................... 82 
 
Figure 4.24: Number of IFNγ+ NK cells, shown as a percentage of NK cells during 
the second drain..  ...................................................................................... 83 
 
Figure 4.25: Number of IFNγ+ CD4+ T cells, shown as a percentage of CD4+ T 
cells during the third drain..  ....................................................................... 84 
 
Figure 4.26: Number of IFNγ+ CD8+ T cells, shown as a percentage of CD8+ T 
cells during the second drain..  ................................................................... 85 
 
Figure 4.27: Number of IFNγ+ NK cells, shown as a percentage of NK cells during 
the second drain..  ...................................................................................... 86 
 
Figure 5.1: Tumor cell injection and treatment schematic..  ................................ 94 
 
Figure 5.2: Survival curve..  ................................................................................ 95 
 
Figure 5.3: Total non-lymphocyte cells in the tumor microenvironment, as a 




Figure 5.4: Total monocyte derived MDSCs in the tumor microenvironment, as a 
percentage of total cells..  ........................................................................... 97 
 
Figure 5.5: Total granulocyte derived MDSCs in the tumor microenvironment, as a 
percentage of total cells..  ........................................................................... 98 
 
Figure 5.6: Total macrophages in the tumor microenvironment, as a percentage of 
total cells..  ................................................................................................. 99 
 
Figure 5.7: M1 macrophages (CD206- MHC II+) in the tumor microenvironment, 
as a percentage of F4\80+ CD11b+ macrophages..  ................................ 100 
 
Figure 5.8: M2 macrophages (CD206+ MHC II-) in the tumor microenvironment, 
as a percentage of F4\80+ CD11b+ macrophages..  ................................ 101 
 
Figure 5.9: Total dendritic cells in the tumor microenvironment, shown as a 
percentage of total cells..  ......................................................................... 102 
 
Figure 5.10: Survival curve..  ............................................................................ 106 
 
Figure 5.11: Tumor size as measured once weekly in 2208L mice (week 3 post 
tumor implant).. ........................................................................................ 107 
 
Figure 5.12: Tumor size as measured once weekly in 2208L mice (week 4 post 
tumor implant).. ........................................................................................ 108 
 
Figure 5.13: Tumor size as measured once weekly in 2208L mice (week 5 post 
tumor implant).. ........................................................................................ 109 
 
Figure 5.14: Tumor size as measured once weekly in 2208L mice (week 6 post 
tumor implant).. ........................................................................................ 110 
 
Figure 5.15: Total MDSCs in the tumor microenvironment, as a percentage of total 
cells..  ....................................................................................................... 111 
 
Figure 5.16: Total macrophages in the tumor microenvironment, as a percentage 
of total cells..  ........................................................................................... 112 
 
Figure 5.17: M1 macrophages in the tumor microenvironment of the breast 2208L 
model, shown as a percentage of macrophages..  ................................... 113 
 
Figure 5.18: Dendritic cells in the tumor microenvironment of the 2208L breast 





Figure 5.19: Dendritic cells in the tumor microenvironment of the 2208L breast 
cancer model, shown as a percentage of total cells..  .............................. 115 
 
Figure 5.20: Mature or activated dendritic cells in the tumor microenvironment of 
the 2208L breast cancer model, shown as a percentage of dendritic cells.. 
 ................................................................................................................. 116 
 
Figure 5.21: Total macrophages in the tumor microenvironment of the VDID8 
ovarian cancer mouse model during week 6 post tumor cell injection (drain 
3)..  ........................................................................................................... 120 
 
Figure 5.22: Peritoneal macrophages in the tumor microenvironment of the VDID8 
model shown as a percentage of macrophages..  .................................... 121 
 
Figure 5.23: Total M1 macrophages as a percentage of cells in DFMO, AZA, and 
AZA+DFMO treated mice compared to mock mice..  ............................... 122 
 
Figure 5.24: Total M2 macrophages as a percentage of cells in DFMO, AZA, and 
AZA+DFMO treated mice compared to mock mice..  ............................... 123 
 
Figure 5.25: Peritoneal macrophages exhibiting an M1-like phenotype positive for 
MHC II and negative for CD206, shown as a percentage of peritoneal 
macrophages..  ......................................................................................... 124 
 
Figure 5.26: Peritoneal macrophages exhibiting an M2-like phenotype negative for 
MHC II and positive for CD206, shown as a percentage of peritoneal 
macrophages..  ......................................................................................... 125 
 
Figure 6.1: Schematic demonstrating hypothesis that DFMO treatment works at 
the tumor tissue site, and is able to promote tissue resident macrophages 





List of Abbreviations 
7AAD: 7-Aminoactinomycin D 
ACK: Ammonium chloride potassium 
ANOVA: Analysis of variance 
ARG1: Arginase 1 
AZA: 5-Azacytidine 
BrdU: Bromodeoxyuridine 
CCR: Chemokine receptor type 2 
CD: Cluster of differentiation 
CRISPR: Clustered regularly interspaced short palindromic repeats 
CSF: Colony-stimulating factor 
CSF1R: Colony-stimulating factor receptor 
dcAdoMet: Decarboxylated S-adenosylmethionine 
DFMO: Difluoromethylornithine 
DNA: Deoxyribonucleic acid 
DNMT: DNA methyl transferase 
DNMTi: DNA methyl transferase inhibitor 
ELISA: Enzyme-linked immunosorbent assay 
ERV: Endogenous retrovirus  
FBS: Fetal bovine serum 
FcR: Fc receptor 
FTE: Fallopian tube epithelium  
xvi 
 
GFP: Green fluorescent protein 
GrB: Granzyme B 
HDACi: Histone deacetylase inhibitor 
HGSOC: High-grade serous ovarian carcinoma 
HPLC: High-performance liquid chromatography 
IFN: Interferon 
IFNGR: Interferon γ receptor 
Ig: Immunoglobulin 
IL: Interleukin 
iNOS2: Nitric oxide synthase 
IP: Intraperitoneal 
LPS: Lipopolysaccharide 
M-CSF: Macrophage colony-stimulating factor 
MDS: Myelodysplastic syndrome 
MDSC: Myeloid-derived suppressor cell 
MHC: Major histocompatibility complex 
MOSE: Mouse ovarian surface epithelium 
NK: Natural killer 
ODC: Ornithine decarboxylase 
OSE: Ovarian surface epithelium 
PAOX: Peroxisomal N(1)-acetyl-spermine/spermidine oxidase 
PBT: Polyamine blocking therapy 
xvii 
 
PD: Programmed death 
PD-L1: Programmed death ligand 
PMA: Phorbol 12-myristate 13-acetate 
qRT-PCR: Real-time polymerase chain reaction 
RAG: Recombination activating gene 
RNA: Ribonucleic acid 
RPMI: Roswell Park Memorial Institute 
SEM: Standard error of the mean 
SMOX: Spermine oxidase 
SPDSY: Spermidine synthase 
SPMSY: Spermine synthase 
SSAT: Spermidine/spermine N(1)-acetyltransferase 
TAM: Tumor associated macrophage 
TGFβ: Transforming growth factor β 
TNF-α: Tumor necrosis factor  
VDID8: VEGF-β-Defensin ID8 
VEGF: Vascular endothelial growth factor 
WT: Wildtype 
1 
Background and Significance 
1.1 Ovarian cancer and its tumor microenvironment 
A patient diagnosed with ovarian high-grade serous ovarian carcinoma 
(HGSOC) today has only a slightly increased survival compared with the same 
patient diagnosed 30 years ago (1). This fact is disturbing given the amount of 
research that has been conducted in   the cancer field. It remains the most deadly 
gynecological malignancy with a high recurrence of 60% (1,2). Nearly 60 new 
cancer drugs received FDA approval in the past 5 years (2012-2017); however 
only one of those drugs was approved to treat ovarian cancer (3). Although ovarian 
cancer is not the most prevalent malignancy, it remains the 5th leading cause of 
death for women, and therefore the need for novel therapeutics is high (1,2). 
One of the biggest challenges related to ovarian HGSOC is its 
immunosuppressive tumor microenvironment, helping the tumor escape immune 
surveillance. Cancer immunotherapy treatment options have grown rapidly in the 
last decade and have demonstrated considerable promise in multiple disease 
types; however, ovarian tumors have thus far not responded well to current 
treatment options such as immune checkpoint blockade therapies using α-PD-1 
and α-PD-L1 (4-7).  Low intra-tumoral CD8+ T cells and high immunosuppressive 
cell populations such as myeloid derived suppressor cells (MDSCs) and 
macrophages are associated with poor prognosis in ovarian cancer and could 
impact the efficacy of these immune therapies (8-11). Drug treatment strategies 
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that alter the tumor and immune cell microenvironment could prolong survival for 
ovarian patients. 
1.2 DNMTis and the antiviral immune response 
One treatment strategy that impacts immune cell populations in the tumor 
microenvironment is epigenetic therapy such as DNA methyl transferase inhibitors 
(DNMTIs) and histone deacetylase inhibitors (HDACIs) (12-18).  5-azacytidine 
(AZA) is a demethylating agent that incorporates into nucleic acids as a cytidine 
analog, which cannot be methylated by DNA methyl transferases (DNMTs). AZA 
is FDA approved for myelodysplastic syndrome (MDS), and low nanomolar doses 
lead to decreased DNA promoter methylation and restored expression of 
hypermethylated genes in cancer (19). Additionally, AZA treatment induces the re-
expression of hypermethylated, silenced endogenous retroviruses (ERVs) in vitro, 
which can elicit an anti-viral, interferon immune response that leads to T cell 
activation in vivo (14,17). Furthermore, AZA treatment of an ovarian cancer mouse 
model leads to increased immune cells in the tumor microenvironment, and 
combination AZA and HDACi sensitized tumors to α-PD-1 therapy (17). While first 
generation HDACIs combined with DNMTIs have demonstrated some promise in 
clinical trials for non-small cell lung cancer (20), there remains a need to discover 
novel treatment strategies that activate the immune system and provide long term 
remission for other solid tumors.   
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1.3 Polyamines as anti-inflammatory agents 
While the impact of epigenetic therapy on the immune system has been well 
established, emerging literature has shown that additional drug therapies can also 
regulate the immune system. The second drug we chose to test in a novel 
combination with 5-azacytidine is α-difluoromethylornithine (DFMO), an inhibitor of 
ornithine decarboxylase (ODC). ODC, a transcriptional target of the oncogene 
MYC, catalyzes a rate limiting step of polyamine synthesis forming putrescine from 
the precursor ornithine (Fig 1.1) (21,22).  
 
Figure 1.1: The enzyme arginase (ARG1) first catalyzes the conversion of arginine to ornithine, 
creating the substrate for ornithine decarboxylase (ODC). ODC then catalyzes the production of 
putrescine from ornithine, forming the first polyamine in the polyamine pathway. Subsequent 
polyamines spermidine and spermine are formed by the enzymes spermidine synthase (SPDSY) 
and spermine synthase (SPMSY) respectively using the aminopropyl group from decarboxylated 
S-adenosylmethionine (dcAdoMet). Once decarboxylated, S-adenosylmethionine can no longer be 
used as a methyl donor in methyltransferase reactions.  Figure reproduced with permission from 
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Casero, et al. Nature Reviews Cancer. (22). SMOX = spermine oxidase; SSAT =  
spermidine/spermine N(1)-acetyltransferase; PAOX = Peroxisomal N(1)-acetyl-
spermine/spermidine oxidase 
 
Polyamines are polycationic alkylamines and in mammalian cells consist of 
spermidine, spermine and their diamine precursor, putrescine.   Polyamines are 
essential for several biological processes including chromatin stability, regulation 
of gene expression at the transcriptional, translational, and posttranslational levels, 
play important roles in ion channel gating, membrane stability and act as free 
radical scavengers (22).  Importantly, the metabolism of and requirements for 
polyamines are frequently dysregulated in cancer (22). This dysregulation, often 
leading to increased tumor polyamine levels is considered a prerequisite for the 
hyperproliferative nature of the cancer cells.  Additionally, the increased 
polyamines may also contribute to an immunosuppressive tumor 
microenvironment. Spermidine regulates pro-inflammatory cytokines and has 
been shown to have anti-inflammatory effects (23). Microglial cells treated with 
spermidine prior to stimulation with lipopolysaccharide (LPS) demonstrated a 
decrease in inflammatory cytokines such as IL-6 and TNF-α (23). Polyamines may 
therefore promote immunosuppression via these anti-inflammatory mechanisms. 
Polyamine blocking therapy (PBT) is a therapeutic strategy that uses an 
inhibitor of ODC, 2-difluoromethylornithine (DFMO) in combination with a 
polyamine transport inhibitor and results in greater polyamine depletion in cells and 
animals as compared to the use of DFMO alone (REF).  This strategy has the 
potential to be used as both an anti-proliferative and pro-inflammatory strategy. 
Researchers found that use of PBT hindered tumor growth in immunocompetent 
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mice but not in athymic mice (24). It would seem that an essential action of the 
PBT was to activate the immune response and prevent tumor escape. If PBT was 
purely anti-proliferative, the athymic mice should have responded to treatment as 
well (24). It was further found that PBT led to decreased levels of myeloid 
suppressor cells and increased levels of CD3 positive T cells (24). Polyamine 
deprivation and PBT was also found to reverse immune abnormalities in the 
spleens of mice (25). Decreased IL-2 production in mice grafted with Lewis lung 
carcinoma recovered after PBT treatment, and an increase in natural killer (NK) 
cells was seen (25). 
DFMO has traditionally been used for its anti-proliferative effects; however, 
these recent findings suggest it may play an important role in activating the 
antitumor immune response (26). Investigators demonstrated that treatment of 
immunocompetent mice with DFMO inhibited tumor growth, and this effect was 
eliminated when RAG1 knockout mice which have no functional T cell immunity 
were given the same treatment (26). DFMO treatment in immunocompetent mice 
was also shown to decrease myeloid-derived suppressor cells (MDSCs) activity 
and increase infiltration of CD8 positive T cells (26). Cancers with high infiltration 
of MDSCs are associated with a poorer prognosis, therefore decreasing the activity 
of these cells could be an effective way to relieve the immunosuppression and 
activate the immune response against the tumor (27). 
Additional evidence in the literature supports the role of polyamines as anti-
inflammatory agents. Pathogens such as the fungi Batrachochytrium dendrobatidis 
use polyamines to diminish immune responses in their prospective hosts (28). High 
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spermidine concentrations have been shown to inhibit lymphocyte proliferation 
(28). Ridding the body of infection from the bacterium Helicobacter pylori, which 
has been shown to increase risk of gastric cancer, is also impacted by polyamines 
(29). One mechanism for controlling H. pylori infection is through production of 
nitric oxide which can kill the bacterium (29). Production of nitric oxide is achieved 
primarily via gastric macrophages which upregulate expression of the enzyme 
iNOS2 that metabolizes arginine to nitric oxide (29,30). The polyamine spermine 
was shown to inhibit translation of inducible iNOS2, and ODC was found to be 
upregulated in macrophages of mice and human gastritis tissue—a condition 
known to be caused by chronic H. pylori infection (29,31). Treatment with DFMO 
was found to restore iNOS2 expression and consequently lower H. pylori 
colonization levels in mice infected with the bacterium (29).  
Also in the case of H. pylori infection, others have found that myeloid-specific 
deletion of ODC increases inflammation and promotes gastric macrophages 
toward an M1 polarization (32). Importantly, an add-back experiment which 
introduced extraneous putrescine rescued the increased inflammation, and 
caused macrophages to reverse their phenotype (32). Taken together, polyamine 
metabolism has critical impacts on myeloid populations through metabolism of 
arginine, making them an attractive target for tumors rich in myeloid populations.  
1.4 TAMs as both pro- and anti-tumorigenic 
Macrophages demonstrate considerable plasticity in their development, 
responding to environmental signals such as cytokines and growth factors that 
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dictate their phenotype (33). Classically polarized or M1 type macrophages are 
considered to be anti-tumorigenic, producing pro-inflammatory cytokines and 
promoting T cell immunity (33-35). These M1 polarized macrophages can also 
have direct cytotoxic effects on tumor cells, killing them via extracellular 
mechanisms (36).  
In contrast, alternatively polarized or M2 type macrophages, normally involved 
in wound repair, are anti-inflammatory and can promote tumorigenesis (33-35). 
Tumors and surrounding stromal cells can produce chemokines, cytokines, and 
growth factors that promote macrophages toward this M2 or pro-tumorigenic 
polarization (36,37).  These M2 macrophages not only dampen the anti-tumor 
immune response by producing regulatory cytokines such as IL-10 and TGFβ, they 
can further directly assist tumors in processes essential for their survival such as 
angiogenesis and metastasis (36).  
At the core of this polarization decision of a developing myeloid cell is how to 
use the metabolite arginine (Fig. 1.2) (30). M1 macrophages, whose differentiation 
is promoted by downstream signaling from IFNγ, upregulate the enzyme iNOS 
which metabolizes arginine to nitric oxide and L-citrulline (30). Via a nitric oxide 
dependent mechanism, these M1 macrophages are capable of promoting tumor 
rejection via T cell recruitment and promotion of T cell immunity (38). Conversely, 
M2 macrophages upregulate expression of the enzyme arginase (ARG1) via 
signaling downstream from cytokines such as IL-4, IL-10, and IL-13 (30,36). 
Arginase metabolizes L-arginine to L-ornithine and urea, and subsequently L-
ornithine can be further metabolized to produce polyamines such as putrescine, 
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spermidine, and spermine. As indicated above, polyamines have been shown to 
have an anti-inflammatory role in the cell, and in fact spermine was shown to inhibit 
synthesis of inflammatory cytokines such as TNFα and IL-1 (39). DFMO, as an 
inhibitor of ODC, has potential to inhibit ARG1 via increased amounts of L-ornithine 
and product inhibition. DFMO treatment of melanoma cell lines was shown to 
decrease arginase enzyme activity (26), and DFMO treatment potentiates nitric 
oxide production in LPS stimulated macrophages (40). Therefore, one critical 
mechanism of action of DFMO is its function at the center of this macrophage 
polarization decision, and thus has great potential to stimulate myeloid cells toward 
an M1, anti-tumorigenic phenotype. 
Figure 1.2: L-arginine metabolism pathways. M1 macrophages upregulate the enzyme iNOS2 (left) 
to mediate T cell recruitment to the tumor, while M2 macrophages upregulate ARG1 which favors 
production of polyamines and a pro-tumor microenvironment (17). 
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Lastly it should be noted that the oncogene MYC comprises approximately 40 
percent of the transcriptional fingerprint of alternatively polarized M2 macrophages 
and is overexpressed in TAMs (36). The enzyme ODC is a transcriptional target of 
MYC, therefore TAMs which overexpress MYC are likely to upregulate ODC 
expression as well, enabling them to metabolize arginine down the polyamine 
pathway (21,22). AZA treatment has been shown to downregulate MYC, therefore 
the addition of AZA to DFMO treatment could further impact macrophage 
polarization (18). DFMO will inhibit the enzyme ODC directly, while AZA can 




2.1 Animal Models 
Female C57BL/6NHsd wild-type (WT) mice (7-8 wk old) were purchased from 
Envigo International Holdings, Inc. (Indianapolis, IN).  Mice were housed at the 
Johns Hopkins Kimmel Cancer Center Animal Resources Core and cared for in 
accordance with the policies of The Johns Hopkins University Animal Care and 
Use Committee and our approved animal protocol. 
2.1.1  VEGF-β-Defensin ID8 Ovarian Cancer Model 
Dr. Katherine Roby developed the ID8 model via mild trypsinization of the 
ovarian surface epithelium, followed by long-term passage in vitro until the cells 
spontaneously immortalized (41). The parental ID8 clone has been further 
modified to enhance its usefulness as a tool by overexpressing VEGF and β-
defensin, making the tumor more aggressive and immunosuppressive (42,43). The 
VEGF-β-Defensin ID8 (VDID8) cells are also positive for Luciferase and green 
fluorescent protein (GFP). While this model has proven to be an excellent research 
tool, it has limitations in representing high-grade serous ovarian cancer in humans 
because it is derived from mouse ovarian surface epithelium, not the fallopian tube, 
and is Trp53 wildtype (44). In mice however, ovarian cancer can arise from either 
fallopian tube epithelium (FTE) or ovarian surface epithelium (OSE) and ID8 is the 
most widely used MOSE model for immunotherapy studies in ovarian cancer. 
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2.1.2  p53-/- ID8 Ovarian Cancer Model 
Mutations in the tumor suppressor TP53 are among the most common 
mutations seen in human ovarian cancers (44). To better study this mutation in 
animal models, Dr. Iain McNeish developed an ID8 tumor cell line null for p53 using 
CRISPR-Cas9 (44). This single mutation accelerated the rate of tumor growth such 
that median survival reduced from approximately 90 days to 60 days.  
 
Figure 2.1: Percent survival of p53-/- ID8 tumor in WT C57BL/6NHsd mice (44). 
2.1.3  2208L Breast Cancer Model 
The 2208L model developed by the Medina and Rosen labs at Baylor college 
of Medicine is also a p53-/- tumor model (45). The model was adapted from whole 
p53 null mice that succumbed to tumors elsewhere in the body prior to developing 
mammary tumors (45). Thus in order to study only breast tumors, mammary glands 
were isolated from 6 week old p53-/- germline BALB/c mice, and transplanted into 
3 week old wildtype BALB/c mice (45). Numerous mammary tumors developed 
and were characterized according to tumor type. The 2208L is an aggressive, 
infiltrating ductal carcinoma-like mouse tumor that is rich in MDSCs (45). Also 
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unique to this model is that the breast cancer cells have not been cultured on 
plastic and have only been passaged in mice, making them a better, less altered, 
model for in vivo tumor conditions (45). 
2.2 Flow Cytometry 
 
Cells were washed and blocked with FcR Blocking Reagent (Miltenyi Biotec 
130-092-575) and stained for cell-surface markers including Live/Dead 
(eBioscience 65-0865-14), CD45 (BD Biosciences 563891), CD3 (BD Biosciences 
560527), CD4 (BD Biosciences 563331), CD8 (BD Biosciences 563152), NK1.1 
(BD Biosciences 562921), F4/80 (BioLegend 123113), CD11b (BioLegend 
101222), MHC II (isotype control 400627; BioLegend 107619), CD206 (BioLegend 
141708), CD11c (BD Biosciences 564079), Ly6C (BD Biosciences 562728), Ly6G 
(BD Biosciences 563005), CD80 (BD Biosciences 553769), and CD86 (BD 
Biosciences 558703). Cells were permeabilized and stained for intracellular IFNγ 
(isotype control 554686; BD Biosciences 554413). Flow cytometry acquisition was 
performed on an LSR II cytometer (BD Biosciences), and data were analyzed 
using FlowJo software version 10.2. 
2.3 Statistical Analysis 
Data were graphed in GraphPad Prism 7.0 and tested for a Gaussian 
distribution using the Shapiro-Wilk test. Significance was determined for sets of 
data with more than two groups using the one-way ANOVA or Kruskal Wallis test 
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dependent upon normality results from the Shapiro-Wilk test. If only two sets of 
data were compared, either the Mann-Whitney (non-parametric) or student’s t test 
(parametric) were used dependent on normality results. Significances in survival 
data were determined by Mantel–Cox (log-rank) test. P values less than 0.05 were 
deemed significant. Outliers were removed from ascites volume datasets and 
ascites immune cell datasets using Peirce’s criterion (46). Significances are shown 
as *P < 0.05, **P < 0.01, and ***P < 0.001 ****P < 0.0001.  
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Chapter 1: AZA and DFMO activate the immune system 
3.1 Introduction 
AZA treatment induces the re-expression of hypermethylated, silenced 
endogenous retroviruses (ERVs) in vitro, which can elicit an anti-viral, interferon 
immune response that leads to T cell activation in vivo (14,17). Furthermore, AZA 
treatment of an ovarian cancer mouse model leads to increased immune cells in 
the tumor microenvironment, and combination AZA and HDACi sensitized tumors 
to α-PD-1 therapy (17). DFMO treatment also alters immune cell populations in the 
tumor microenvironment (26). Investigators demonstrated that treatment of 
immunocompetent mice, but not RAG1 knockout mice, inhibited tumor growth, 
decreased MDSC activity and increased infiltration of CD8+ T cells (26). Since 
both single agents have demonstrated impacts on the immune system, we tested 
whether the two combined agents would have a synergistic effect in the VDID8 
ovarian cancer mouse model.  
3.2 Methods 
To test the hypothesis that addition of DFMO to therapy using the DNMTi AZA 
would reduce tumor burden and improve overall survival in a mouse model of 
ovarian cancer, immunocompetent C57BL/6 mice were injected intraperitoneally 
(IP) with 250,000 VDID8 syngeneic MOSE cells. Mice were treated IP with AZA 
(0.5 mg/kg) or saline vehicle, DFMO (2% in water), or combination AZA and DFMO 
beginning three days post tumor injection (Fig 3.1). Hemorrhagic ascites fluid 
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consistently develops at approximately 4-5 weeks post VDID8 injection and is an 
accurate measurement of tumor burden in mice, allowing observation of tumor 
growth in real time (42,43).  
 
When ascites fluid is collected from the mice, the cells obtained represent the 
tumor microenvironment and can be further analyzed to help illustrate the mixed 
population of cells surrounding the tumor. Ascites was collected, filtered, incubated 
in ACK buffer (Quality Biological) to lyse red blood cells, and washed. The 
mononuclear cells collected were then cultured for four hours in RPMI (Corning) 
with 10% FBS in the presence of phorbol 12-myristate 13-acetate (PMA) and 
ionomycin to stimulate cells, and brefeldin A and monensin (Invitrogen 00-4975-
93) to cause aggregation of secreted proteins inside the cell. Cells were 
subsequently washed and stained with a panel of antibodies (one million cells per 
mouse) in accordance with experimental protocol 2.2 Flow Cytometry. Remaining 
cells from each treatment arm were pooled, washed, and pellets were frozen at -
80C for later polyamine analysis. Polyamines were analyzed via high-performance 
liquid chromatography (HPLC) as previously described (47). In vitro polyamines 
were assessed by culturing VDID8 cells in 10% FBS RPMI + gentamicin for one 
week prior to beginning 10 day treatment. Cells were treated with 500nM 
AZA/saline for 10 days and 5mM DFMO/water for 3 days. AZA+DFMO cells were 
treated with 500nM AZA for the first 7 days, and 500nM AZA + 5mM DFMO for the 





3.3.1  Combination treatment reduces tumor burden and increases survival 
To confirm that DFMO inhibits ODC in the model systems used, VDID8 cells 
were treated in vitro and in vivo and polyamine levels were determined (Fig 3.2. 
3.3). In vitro treatment of VDID8 tumor cells led to a significant decrease in 
putrescine and spermidine with DFMO alone and when combined with AZA.  
However, AZA alone appeared to have a stimulatory effect on putrescine and 
spermidine synthesis (Fig 3.2). In bulk ascites cells from treated animals, 
combination treatment led to a decrease in all three polyamines, including 
spermine (Fig 3.3).  No significant changes to the polyamine pools were observed 
with AZA treatment alone, but putrescine and spermidine were decreased 
(although not significantly) by DFMO treatment (Fig 3.3). 
Volumetric measurements of hemorrhagic ascites fluid are directly correlated 
to tumor burden in the VDID8 model of ovarian cancer (42,43). Mice treated with 
single agent AZA or DFMO have reduced tumor burden initially after the first 
ascites drain (week 4), but subsequently present with higher tumor burden at week 
5 compared to mice treated with combination therapy (Fig. 3.4 and 3.5). Mice 
treated with combination therapy also exhibited the largest increase in overall 
survival with a median survival of 59 days compared to that of single agent AZA or 
DFMO of approximately 44 days (Fig. 3.6).  Although single agent treatment with 
AZA or DFMO compared to vehicle treatment significantly increases total numbers 
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of lymphocytes, these numbers are not further enhanced with combination 
AZA+DFMO treatment (Fig. 3.7 and 3.8).   
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Figure 3.1: Tumor cell injection and treatment schematic. Mice were injected IP 
with 250,000 VDID8 cells and treated with 0.5 mg/kg of AZA/saline IP 5 days a 
week, every other week. 2% DFMO was provided in water bottles. Mice were 
treated throughout the duration of the experiment. Upon 25-30% weight gain, 




Figure 3.2: VDID8 cells were cultured in 10% FBS RPMI + gentamicin for one 
week prior to beginning 10 day treatment. Cells were treated with 500nM 
AZA/saline for 10 days and 5mM DFMO/water for 3 days. AZA+DFMO cells were 
treated with 500nM AZA for the first 7 days, and 500nM AZA + 5mM DFMO for 
the final 3 days of treatment. High-performance liquid chromatography (HPLC) 
analysis of polyamine levels in cultured, treated VDID8 cells are shown. n = 3.
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Figure 3.3: Bulk ascites fluid was collected from individual mice treated with 
DFMO, AZA, or AZA+DFMO. Bulk ascites cells were lysed and washed and 
remaining cells were prepped for HPLC analysis of polyamine levels. n = 4-10. 
All data were tested for a Gaussian distribution and found to be normal using 




Figure 3.4: Tumor burden, represented by ascites volume, 4 weeks post tumor 
injection. Representative data (mean +/- SEM shown). n = 10; four biological 
replicates. Data found to be normal via Shapiro-Wilk test. Significance determined 
using one-way ANOVA; statistical outliers removed using Peirce’s criterion. 
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Figure 3.5: Tumor burden, represented by ascites volume, 5 weeks post tumor 
injection. Representative data (mean +/- SEM shown). n = 10; four biological 
replicates. Data found to be normal via Shapiro-Wilk test. Significance determined 




Figure 3.6: Representative survival curve (median survival in days); n = 10; four 





Figure 3.7: Flow cytometry plots of SSC vs. FSC demonstrating an increase in 
lymphocyte populations in ascites fluid at week 5 post tumor injection with AZA, 
DFMO, and AZA+DFMO treatment. Range of total lymphocyte population 
percentages are included in the upper left hand corner for each plot. 
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Figure 3.8: Total lymphocyte populations in week 5 bulk ascites fluid of mice; n = 
14-21. Data were tested for a Gaussian distribution using Shapiro-Wilk test and 
found to be normal after log transformation. Significance was determined using 
one way ANOVA.  
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3.3.2  AZA+DFMO has few impacts on cell cycle 
Because DFMO is FDA approved as an anti-proliferative agent for conditions 
such as facial hirsutism, we needed to investigate whether the efficacy of 
combination therapy could be due simply to anti-proliferative effects or perhaps 
increased cell death or apoptosis (22). We conducted in vivo and in vitro cell-cycle 
analyses, determined by BrdU incorporation and 7-AAD staining of DNA content. 
In vivo and in vitro data showed that the majority of tumor cells are in the G0-G1 
phase (Fig. 3.9 and 3.10). In both sets of data, it appears that AZA+DFMO 
treatment leads to a G2-M block (Fig. 3.9 and 3.10). While in vitro data shows a 
significant reduction in S phase cells with treatment, in vivo conditions, which are 
influenced by many more variables, differ (Fig. 3.9 and 3.10). This could be due to 
the greater reduction of polyamines seen in vitro versus in vivo (Fig. 3.2 and 3.3). 
These tumor cell data cannot wholly account for the anti-tumorigenic effect of 
combination AZA+DFMO in our model. The changes in apoptosis at the low doses 
of AZA and DFMO used in our study are small as we have previously reported and 
proliferation in vivo is not decreased (17,19). The data do suggest that the 
combination of AZA and DFMO may lead to an increase of cells in G2-M and this 
could play a role in the anti-tumorigenic effect observed by combination treatment. 
Additionally, microRNA gene expression data was obtained for tumor cells after 
both in vitro culture with DFMO, AZA, and AZA+DFMO, and from GFP+ sorted 
cells from mice treated in vivo (Fig. 3.11 and 3.12). Using an apoptosis gene set 
enrichment analysis, there were no significant increases in expression of apoptotic 
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related genes after treatment with AZA, DFMO, or combination AZA+DFMO. Gene 
enrichment maps provided below for both in vitro and in vivo results. 
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Figure 3.9: Cell cycle analysis of in vitro AZA+DFMO treatment of VDID8 cells. 
There are no statistically significant differences among apoptotic cells. 
AZA+DFMO in vitro leads to a significant increase in G2-M phase cells. 
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Figure 3.10: Cell cycle analysis of in vivo AZA+DFMO treatment of mice previously 
injected IP with VDID8 cells. There are no statistically significant differences 




Figure 3.11: Gene set enrichment analysis for DFMO, AZA, and AZA+DFMO 
treated VDID8 cells. No major fold changes in gene expression were observed 
with treatment compared to mock cells. 
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Figure 3.12: Gene set enrichment analysis for GFP+ isolated tumor cells from 
mice treated with DFMO, AZA, and AZA+DFMO. No major fold changes in gene 
expression were observed with treatment compared to mock mice.
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3.3.3  Combination treatment leads to increased lymphocyte populations 
To pursue further whether changes in lymphocyte populations might account 
for the dramatic increase in survival observed with AZA+DFMO combination 
therapy, the numbers and activity of specific lymphocyte subpopulations in 
hemorrhagic ascites fluid at week 5 post tumor injection were analyzed. Single 
agent AZA or DFMO led to significant increases in T cell, NK cell, and IFNγ+ 
lymphocyte populations examined in the tumor microenvironment (Fig 3.13 – 
3.19). In most cases, combination therapy did not alter immune populations over 
what was observed with single agents (Fig 3.13 – 3.18).  The exception however, 
was a significant increase in IFNγ+ NK cells observed in combination treated mice 
versus AZA or DFMO alone (Fig 3.19). 
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Figure 3.13: Number of total T cells shown as a percent of total cells, isolated from 




Figure 3.14: Number of total NK cells shown as a percent of total cells, isolated 
from ascites fluid of mice at week 5 post tumor injection.  
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Figure 3.15: Number of total CD4+ “Helper” T cells shown as a percent of total 




Figure 3.16: Number of total CD8+ cytotoxic T cells shown as a percent of total 
cells, isolated from ascites fluid of mice at week 5 post tumor injection. 
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Figure 3.17: Number of IFNγ+ CD4+ T cells, shown as a percentage of CD4+ T 
cells. IFNγ can be considered a marker of T cell activation, and combination 




Figure 3.18: Number of IFNγ+ CD8+ T cells, shown as a percentage of CD8+ T 
cells. AZA+DFMO combination treatment trends toward an increase in activated 
CD8+ T cells, but is not significant. 
39 
 
Figure 3.19: Number of IFNγ+ NK cells, shown as a percent of NK cells. 
Combination treatment leads to significant increases in these IFNγ+ cells 
compared to both single treatment DFMO or AZA.  
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3.3.4  Addition of α-PD-1 does not provide added benefit 
It was hypothesized that the observed increase in IFNγ+ cells in the model 
could lead to an increase in PD-L1 expression on the surface of tumor cells, 
possibly sensitizing the tumor to α-PD-1 therapy. Surface PD-1 expression on T 
cells is a signature of immune tolerance, and when engaged with its ligand PD-L1 
on tumor cells, can limit the T cell’s ability to proliferate and perform its effector 
functions (48,49). We found that GFP+ tumor cells collected from ascites fluid were 
positive for PD-L1, suggesting that interfering with the PD-1/PD-L1 axis may 
improve treatment outcome in these mice (Fig 3.20 and 3.21). No changes were 
observed in the number of PD-1 expressing T cells however, with single agent or 
combination treatment (Fig 3.20 and 3.21).  Nevertheless, there is a population of 
PD-1+ T cells thus antibody treatment may be beneficial.  
Mice were treated with four, 200ug doses of α-PD-1 at days 17, 20, 24, and 27 
post tumor injection, as shown in Fig 3.24. This α-PD-1 regimen was found to 
successfully improve survival in a combination AZA+HDACi treatment regimen, 
and was therefore tested in this model (17). Addition of α-PD-1 to the combination 
of DFMO and AZA treatment did not further decrease tumor burden in the mice, 
nor did it increase survival (Fig 3.25-3.28). The lack of response to α-PD-1 therapy 
suggests that a T cell response may not be the primary mechanism of action in 




Figure 3.20: Number of PD-L1+ tumor cells, collected from ascites fluid of mice at 





Figure 3.21: Number of PD-L1+ tumor cells, collected from ascites fluid of mice at 




Figure 3.22: Number of PD-1+ CD4+ T cells, shown as a percentage of CD4+ T 
cells. No changes with treatment were observed, and total PD-1 expressing cell 





Figure 3.23: Number of PD-1+ CD8+ T cells, shown as a percentage of CD8+ T 
cells. No changes with treatment were observed, and total PD-1 expressing cell 





Figure 3.24: Treatment regimen for α-PD-1 therapy. Four, 200ug doses of 
antibody or IgG control were administered IP to mice at days 17, 20, 24, and 27 










Figure 3.26: Addition of α-PD-1 to DFMO provided a slight benefit in survival to 









Figure 3.28: Addition of α-PD-1 to combination AZA+DFMO provided no survival 
benefit to mice, and in fact slightly decreased survival of these mice. 
50 
3.4 Discussion 
Combination epigenetic and polyamine reducing therapy is an effective 
treatment strategy for slowing the progression of ovarian cancer in 
immunocompetent mice, and significantly prolonging survival. This treatment 
regimen represents the first combination of these two drug therapies in mice, and 
the first use of DFMO in an immunocompetent mouse model for ovarian cancer 
(46). While slight impacts to the cell cycle were observed in the form of a G2-M 
block with AZA+DFMO treatment, more dramatic changes were seen in the overall 
tumor microenvironment, which comprises the bulk of ascites cells. Treatment with 
AZA alone led to increased lymphocytes and an increase in IFNγ+ NK cells, CD4+ 
T cells, and CD8+ T cells, as has been demonstrated before (14,18,19).  Signaling 
of IFNγ via its receptor IFNGR1 on tumor cells can lead to increased expression 
of PD-L1 on tumor cells, thereby making this increase in IFNγ an attractive 
candidate for α-PD-1 therapy. However, α-PD-1 therapy had no significant impact 
on survival in this model when added to the combination AZA and DFMO.  These 
results are in contrast to previous studies using AZA and HDACi where the addition 
of α-PD-1 produced a significant therapeutic response (18). Histone acetylation is 
essential for transcription of IFNγ, therefore the use of an HDACi may explain the 
sensitization to α-PD-1 therapy previously seen, as increasing histone acetylation 
even further increased IFNγ levels in lymphocytes (47).  These data suggest that 
there may be additional benefit of adding an HDACi to the AZA + DFMO 
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combination if α-PD-1 is to be used, if such a combination could be used with 
acceptable levels of  toxicity. 
While the addition of α-PD-1 modestly decreased survival in Fig 3.28, it is our 
belief that a difference in median survival of 2 days could likely represent a subtle 
benefit or could be explained by experimental variability. Other potential 
explanations for the difference in survival could be engagement of the antibody on 
PD-1 positive cells, causing inhibitory signaling downstream rendering the cells 
less effective. Action of this antibody is beneficial to block interactions with PD-L1 
positive tumor cells; but perhaps when antibody is given in the AZA+DFMO treated 
mice, there is not a high enough tumor burden for action of the antibody to be 
effective, and instead it engages with PD-1 positive T cells only, inhibiting their 
activity. Furthermore, combination treated AZA+DFMO mice have the lowest 
number of PD-L1 positive tumor cells in the tumor microenvironment (Fig 3.23), 
which may explain why addition of α-PD-1 was not beneficial.  
Although these increased IFNγ+ pools of lymphocytes did not sensitize the 
tumor to α-PD-1 therapy, this important cytokine acts not only on tumor cells 
themselves, but also on surrounding myeloid populations (36). Downstream 
signaling of IFNγ promotes a myeloid cell to differentiate into an M1 polarized cell, 
capable of activating T cells via its upregulation of MHC II surface molecules and 
able to kill tumor cells via nitric oxide dependent mechanisms (36). Investigation 
of the myeloid and macrophage populations in the tumor microenvironment is thus 
the next step in determining how the combination AZA+DFMO results in such a 
significant survival benefit (Fig 3.6) in this ovarian cancer mouse model.  
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Chapter 2: AZA+DFMO alter TAMs and promote M1 polarization 
4.1 Introduction 
The DNMTi AZA has been shown to decrease macrophages in the VDID8 
model (17,18); however, this work did not distinguish the macrophage phenotype 
any further. The oncogene MYC is overexpressed in TAMs and its transcriptional 
targets promote polarization of the pro-tumorigenic M2 macrophage (36).  AZA has 
been shown to decrease expression of MYC in a non-small cell lung cancer model, 
thus treatment with AZA may reduce M2 polarization (18). Furthermore, DFMO 
treatment decreases enzyme activity of the essential M2 enzyme arginase, further 
inhibiting development of this phenotype (26,30). Taken together, combination 
AZA+DFMO has the potential to not only decrease TAMs in the tumor 
microenvironment, but perhaps inhibit their polarization toward an M2 
macrophage. The observed increases in IFNγ+ lymphocytes may additionally 
promote M1 polarization. We therefore investigated macrophage populations in 
the tumor microenvironment of our AZA+DFMO treated mice. 
4.2 Methods 
Immunocompetent C57BL/6 mice were injected IP with 250,000 VDID8 
syngeneic MOSE cells. Mice were treated IP with AZA (0.5 mg/kg) or saline 
vehicle, DFMO (2% in water), or combination AZA and DFMO beginning three 
days post tumor injection (Fig 3.1). Hemorrhagic ascites fluid consistently develops 
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at approximately 4-5 weeks post VDID8 injection and is an accurate measurement 
of tumor burden in mice, allowing observation of tumor growth in real time (42,43). 
When ascites fluid is collected from the mice, the cells obtained represent the 
tumor microenvironment and can be further analyzed to help illustrate the mixed 
population of cells surrounding the tumor. Ascites was collected, filtered, incubated 
in ACK buffer (Quality Biological) to lyse red blood cells, and washed. Cells were 
blocked with FcR Blocking Reagent (Miltenyi Biotec 130-092-575) and stained for 
cell-surface markers including Live/Dead (eBioscience 65-0865-14), CD45 (BD 
Biosciences 563891), F4/80 (BioLegend 123113), CD11b (BioLegend 101222), 
MHC II (isotype control 400627; BioLegend 107619), CD206 (BioLegend 141708), 
CD11c (BD Biosciences 564079), and GrB (BioLegend 108407). Flow cytometry 
acquisition was performed on an LSR II cytometer (BD Biosciences), and data 
were analyzed using FlowJo software version 10.2. 
To assess gene expression of macrophages in the tumor microenvironment, 
processed ascites cells were suspended in PBS and sorted immediately on a BSL-
2 FACSAria II. M1 macrophages were sorted on a gate as follows: CD45+ L/D- 
F4\80+ CD11b+ MHC II+ CD206- CD11c-. M2 macrophages were sorted on a gate 
as follows: CD45+ L/D- F4\80+ CD11b+ MHC II- CD206+ CD11c-. Total RNA was 
isolated from sorted macrophages using TRIzol reagent according to the 
manufacturer’s protocol (Invitrogen, Carlsbad, CA). 200 ng of RNA was used for 
cDNA synthesis using qScript cDNA SuperMix (Quanta Biosciences, 
Gaithersburg, MD), followed by SYBR green-mediated real-time PCR (Universal 
SYBR Green Supermix, BioRad, Hercules, CA) using custom primers specific for 
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Arg1, Fizz1, and iNOS2. In each experiment, samples were performed in duplicate, 
normalized to β-actin as an internal control, and fold change in expression relative 
to M1 or M2 macrophage was determined using the 2-ΔΔCt algorithm. 
Thermocycling was performed on a Bio-Rad iQ2 real-time PCR detection system 
and data collected using the iQ5 optical system software. 
ELISA assays were performed on serum collected from bulk ascites fluid of 
individually treated mice via centrifugation at low speed (1000rpm) for 15 minutes. 
Supernatant was collected and stored at -80C. Circulating CSF-1 levels in mice 
treated with IgG vs. CSF1R was detected using an ELISA kit (R&D Systems Kit 
#MMC00) according to instructions. 
4.3 Results 
4.3.1  AZA+DFMO reduce population of macrophages 
Myeloid immune cell populations were next examined to determine whether a 
decrease in immunosuppression may account for the striking differences in 
survival. Myeloid derived suppressive cells (MDSCs) are suppressive immune 
cells sometimes present in the tumor microenvironment, high levels of which are 
associated with a poor prognosis in ovarian cancer (10). No significant decrease 
in non-lymphocyte or MDSC populations were observed after treatment with AZA 
and DFMO (Fig 4.1 and 4.2). Instead, total macrophage populations in the tumor 
microenvironment were consistently decreased with AZA treatment, and 
decreased even further with the addition of DFMO (Fig 4.3). 
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Macrophages are professional antigen presenting cells capable of activating T 
cells. Surface expression of MHC II is essential for interaction with T cells, and the 
number of MHC II positive cells was increased with AZA, DFMO, and AZA+DFMO 
treatment compared to vehicle (Fig 4.4 and 4.5). Importantly, MHC II expressing 
cells were increased significantly with combination treatment compared to single 
agent AZA, suggesting a possible explanation for the dramatic increase in survival 
(Fig 4.4). In contrast, untreated mice had high populations of macrophages 
negative for the MHC II surface protein (Fig 4.5). These data suggest that 





Figure 4.1: Total non-lymphocyte cells in the tumor microenvironment, as a 
percentage of total cells collected from ascites fluid. No changes with treatment 




Figure 4.2: Total MDSCs in the tumor microenvironment, as a percentage of total 
cells. No changes with treatment were observed, and overall populations of 




Figure 4.3: Total macrophages in the tumor microenvironment as a percentage of 
total cells. collected from ascites fluid. Single agent DFMO and single agent AZA 
both significantly reduce macrophage populations; however combined 
AZA+DFMO even further decreases macrophages, significantly compared to 




Figure 4.4: Macrophages positive for the surface marker MHC II, and therefore 
capable of presenting antigen to CD4+ T cells. Data presented as a percentage of 




Figure 4.5: Macrophages negative for the surface marker MHC II, and therefore 
unable to present antigen to CD4+ T cells. Data presented as a percentage of 
F4\80+ CD11b+ macrophages. 
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4.3.2  Treatment promotes M1 over M2 polarization 
Next, surface markers were examined to distinguish between classical (M1) 
and alternative (M2) polarized macrophages. High populations of M2 
macrophages are associated with a poor prognosis due to their ability to promote 
tumor growth (9,11,33). Because the surface marker CD206 is upregulated on M2 
macrophages, flow cytometry was used to analyze macrophages high for CD206 
and low for MHC II—a surface marker for M1 macrophages. Although total 
macrophages were decreased by the treatments, an increase in M1 macrophages 
were observed in the remaining macrophage population for all treatment groups 
(Fig 4.6), as well as a decrease in M2 macrophages (Fig 4.7). MHC II- CD206+ 
and MHC II+ CD206- macrophages were then sorted via flow cytometry, and RNA 
was isolated to perform RT-PCR on M1- and M2-specific genes (30,50-52). As 
expected, CD206+ macrophages demonstrated increased expression of Arg1 and 
Fizz1 compared to CD206- macrophages (Fig 4.8 and 4.9), and MHC II+ 
macrophages had increased expression of iNOS2 compared to MHC II- 
macrophages (Fig 4.10).  These data confirm that macrophages expressing high 
levels of CD206 in our model also retain gene expression patterns that are 
characteristic of alternatively polarized M2 macrophages. 
Interestingly, the decrease in M2 macrophages observed in AZA+DFMO 
treated mice was not a durable response, and as tumor burden increased in these 
mice, the relative proportion of M2 macrophages increased as well (Fig 4.11). 
Macrophages in vehicle treated mice were therefore assessed at three different 
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time points to determine whether M2 macrophages increase as the disease 
progresses. Indeed, relative levels of M2 macrophages increased as tumor burden 
increased in these mice, suggesting the importance of macrophages in disease 
progression of this ovarian cancer model (Fig. 4.12).  
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Figure 4.6: M1 macrophages (CD206- MHC II+) in the tumor microenvironment, 
as a percentage of F4\80+ CD11b+ macrophages. AZA+DFMO treated mice 
demonstrate significantly increased populations of M1 macrophages, compared to 




Figure 4.7: M2 macrophages (CD206+ MHC II-) in the tumor microenvironment, 
as a percentage of F4\80+ CD11b+ macrophages. AZA+DFMO treated mice 
demonstrate significantly decreased populations of M2 macrophages, compared 








Figure 4.8: qRT-PCR for Arg1 on sorted macrophages. Data confirms that 





Figure 4.9: qRT-PCR for Fizz1 on sorted macrophages Data confirms that 






Figure 4.10: qRT-PCR for iNOS2 on sorted macrophages. Data confirms that 




Figure 4.11: a) Representative flow cytometry data shown for one mouse treated 
with combination AZA+DFMO in vivo. At a later time point, there are significantly 
increased proportions of M2 macrophages high in CD206 and low in MHC II 
surface expression. b) Paired tumor burden, represented by ascites volume for the 
same mouse whose cells are shown in 4.11a. The mice’s tumor burden is 
increased at the later time point, coinciding with an increase in M2 macrophages. 




Figure 4.12: Percentage of M2 macrophages (MHCII- CD206+) increase with 
tumor burden in vehicle treated mice. Drain 1 was performed at week 4 post tumor 
cell injection; drain 2 at week 5 and drain 3 at week 6.
70 
4.3.3  Macrophage depletion diminishes AZA+DFMO efficacy 
To test whether the increase in M1 macrophages was important in the response 
to AZA and DFMO treatment, macrophages were blocked in the ovarian cancer 
mouse model using an antibody to CSF1R, an essential growth receptor for 
macrophages (53) (Fig 4.13). Treatment with α-CSF1R resulted in decreased 
macrophages in the tumor microenvironment (Fig 4.14) and a consequential 
increase in M-CSF levels in ascites fluid as measured by ELISA (Fig 4.15). 
Increased M-CSF indicates that the α-CSF1 receptor block antibody is functional, 
as more ligand (M-CSF) is free, and less ligand is engaged with its receptor (53).  
Initially, the AZA+DFMO combination treatment still resulted in decreased 
tumor burden in mice, even with the observed decrease in macrophages; however, 
over time, tumor burden increased more rapidly in AZA+DFMO mice receiving α-
CSF1R (Fig 4.16 and 4.17). This depletion in macrophages also led to a decrease 
in overall survival, compared with AZA+DFMO mice that received IgG control (Fig 
4.18).  
Analysis via flow cytometry of M1 and M2 surface markers showed that with 
IgG control, AZA+DFMO mice had increased M1 macrophages and decreased M2 
macrophages compared to vehicle, as was previously seen (Fig 4.19 and 4.20; Fig 
4.6 and 4.7). Interestingly, while AZA+DFMO mice maintained low M2 
macrophages in the presence of α-CSF1R (consistent with the action of α-CSF1R, 
Fig 4.14), M1 macrophages were significantly decreased compared to 
AZA+DFMO mice receiving IgG control (Fig 4.19 and 4.20). These results indicate 
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that the presence of M1 macrophages is important for the mechanism of action of 
this combination drug therapy, as AZA+DFMO treated mice receiving α-CSF1R 
had decreased survival and increased tumor burden compared to IgG control. 
Also important to note from this data is the fact that simply decreasing 
macrophages in this model had no benefit to survival (Fig. 4.18), even though M2 
macrophages were decreased as a result of α-CSF1R (Fig. 4.21). It appears that 
the re-programming and re-directing of macrophages to the M1 polarization 
phenotype is important, not necessarily decreasing M2 macrophages. Lastly, mice 
treated with AZA+DFMO in the presence of CSF1R showed the previously 
observed increase in activated, IFNγ+ CD4 T cells, CD8 T cells, and NK cells 
during both the second and third drain (Fig. 4.22 – 4.27); thus, depletion of 
macrophages did not impact the lymphocyte response. This data may suggest that 
the M1 macrophages are not only activating T cells as part of an adaptive 






Figure 4.13: Treatment regimen for α-CSF1R block antibody or IgG control 
antibody. Three, 200ug doses of antibody were administered IP to mice prior to 
injection of VDID8 tumor cells to deplete macrophages for the duration of tumor 
development. Twice weekly 200ug doses of antibody were also administered IP 




Figure 4.14: Significantly reduced macrophage population, as a percentage of 
total cells, with α-CSF1R treatment. Decrease observed at week 7 on schematic 
in Fig 4.11, otherwise known as the first ascites drain. 
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Figure 4.15: Significantly increased circulating M-CSF cytokine levels in bulk 





Figure 4.16: Tumor burden represented by ascites volume in mice treated with 
AZA+DFMO in presence of CSF1R antibody or IgG control during the second drain 
(week 8 on schematic in Fig 4.11). 
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Figure 4.17: Tumor burden during the third drain (week 9 on schematic in Fig 4.11) 
demonstrating an increase in tumor burden in AZA+DFMO mice receiving CSF1R. 
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Figure 4.18: Survival curve of AZA + DFMO treated mice receiving CSF1R 
antibody. Mice with decreased macrophages due to the antibody demonstrated a 




Figure 4.19: M1 macrophages (CD206- MHC II+) analyzed via flow cytometry at 





Figure 4.20: M2 macrophages (CD206+ MHC II-) analyzed via flow cytometry at 
the second drain. M2 macrophages were reduced in both AZA+DFMO treatment 
arms, compared to mock treated mice. 
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Figure 4.21: M2 macrophages (CD206+ MHC II-) analyzed via flow cytometry at 
the first drain in mock mice receiving either α-CSF1R or IgG control. M2 




Figure 4.22: Number of IFNγ+ CD4+ T cells, shown as a percentage of CD4+ T 
cells during the second drain. IFNγ can be considered a marker of T cell activation, 
and combination AZA+DFMO leads to increased activated CD4+ T cells even in 
the presence of α-CSF1R block. 
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Figure 4.23: Number of IFNγ+ CD8+ T cells, shown as a percentage of CD8+ T 
cells during the second drain. IFNγ can be considered a marker of T cell activation, 
and combination AZA+DFMO leads to increased activated CD8+ T cells even in 
the presence of α-CSF1R block. 
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Figure 4.24: Number of IFNγ+ NK cells, shown as a percentage of NK cells during 
the second drain. IFNγ can be considered a marker of NK cell activation, and 
combination AZA+DFMO leads to increased activated NK cells even in the 




Figure 4.25: Number of IFNγ+ CD4+ T cells, shown as a percentage of CD4+ T 
cells during the third drain. IFNγ can be considered a marker of T cell activation, 
and combination AZA+DFMO leads to increased activated CD4+ T cells even in 





Figure 4.26: Number of IFNγ+ CD8+ T cells, shown as a percentage of CD8+ T 
cells during the second drain. IFNγ can be considered a marker of T cell activation, 
and combination AZA+DFMO leads to increased activated CD8+ T cells even in 




Figure 4.27: Number of IFNγ+ NK cells, shown as a percentage of NK cells during 
the second drain. IFNγ can be considered a marker of T cell activation, and 
combination AZA+DFMO leads to increased activated NK cells even in the 
presence of α-CSF1R block. 
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4.4 Discussion 
Analysis of the tumor microenvironment after the combination treatment with 
AZA and DFMO indicates that changes to macrophage polarization are critically 
important in this model. AZA treatment has been shown to decrease macrophages 
in the tumor microenvironment, though no distinction was made in these studies 
as to the polarization status of these macrophages (17,18). As the understanding 
of macrophages deepens, research has discovered that these cells once thought 
of as permanent, differentiated cells, are in fact quite plastic and able to respond 
to multiple signals including cytokines and chemokines that direct their behavior 
and alter their phenotype. Classically polarized M1 macrophages, induced by 
cytokines such as IFNγ and IL-12, upregulate expression of MHC II and can have 
tumoricidal functions. M1 macrophages metabolize arginine via iNOS to nitric 
oxide (NO), creating an oxidizing environment that is damaging to surrounding 
cells. DFMO treatment has been found to potentiate NO production in LPS-
stimulated macrophages in vitro (40). Additionally, DFMO, via product inhibition 
through the increase in ODC substrate, ornithine, inhibits the enzyme arginase I, 
which is essential for function of alternatively polarized M2 macrophages. Inhibition 
of arginase I could lead to increased amounts of its substrate arginine, potentially 
providing more of the metabolite for use by M1 macrophages and iNOS. We 
hypothesize that treatment with DFMO may therefore increase M1 macrophages 
by making more of its essential metabolite arginine available, while AZA may help 
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increase M1 macrophages via its interferon response and production of IFNγ, a 
cytokine which drives M1 polarization. 
 Depletion of macrophages in the tumor microenvironment using a CSF1R 
antibody significantly diminished the efficacy of combination AZA and DFMO, and 
decreased the levels of M1 macrophages while maintaining levels of IFNγ+ 
lymphocytes. Tumor burden recurred more rapidly and survival was diminished in 
mice with fewer macrophages, suggesting that these M1 macrophages could have 
a tumoricidal role in ovarian tumors. This work represents the first combination of 
these two distinct treatment strategies in any cancer. The impact of AZA and 
DFMO on macrophages in the tumor microenvironment may not be specific to 
ovarian cancer, and could therefore possibly translate to other macrophage-rich 
tumors such as breast and pancreatic cancers. Furthermore, the use of two well-
tolerated and clinically approved drugs offers potential to test a third drug in 
combination to further prolong survival. Exploration of additional drugs that 
potentiate M1 macrophages is important, as these tumoricidal cells have potential 
to decrease tumor burden and help activate the immune system against cancer.
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Chapter 3: AZA+DFMO in solid tumor models 
5.1 Introduction 
While the results seen in the VEGF-β-Defensin ID8 model for high grade serous 
ovarian cancer are encouraging, it is important to determine whether this drug 
combination could be applicable in other forms of solid tumor, and perhaps other 
tumors rich in macrophages. The p53-/- ID8 ovarian tumor cell line developed by 
the McNeish lab forms both hemorrhagic ascites and small solid tumors along the 
ovaries and bladder (44). Importantly, the hemorrhagic ascites that develops in this 
model is not correlated with survival; thus, as the model currently exists, ultrasound 
is the only imaging technique available to monitor tumor burden in these mice (44). 
Another limitation of the VDID8 model is that it doesn’t accurately model the most 
common mutations seen in high grade serous ovarian cancer (HGSOC), including 
but not limited to Trp53, Brca1, Brca2, Nf1, and Rb1 (44). In fact, the McNeish lab 
found that the parental ID8 cell line developed by Dr. Roby in 2000 was wildtype 
for all of these common HGSOC mutations (44). Therefore studying the 
combination AZA+DFMO in a model with mutations common to HGSOC is 
essential in determining how the drugs may work in patients. 
In addition to testing AZA+DFMO in a p53-/- HGSOC mouse model, we decided 
to test the drug combination in a breast cancer model that is also p53 null. The 
2208L model developed by the Medina and Rosen labs at Baylor college of 
Medicine is as mentioned above, also a p53-/- tumor model (45). The 2208L is an 
aggressive, infiltrating ductal carcinoma-like mouse tumor that is rich in MDSCs.  . 
90 
Also unique to this model is that the breast cancer cells have not been cultured on 
plastic and have only been passaged in mice, making them a better, less altered, 
model for in vivo tumor conditions (45).  
5.2 Methods 
Immunocompetent C57BL/6 mice were injected IP with 5,000,000 p53-/- ID8 
syngeneic MOSE cells. Mice were treated IP with AZA (0.5 mg/kg) or saline 
vehicle, DFMO (2% in water), or combination AZA and DFMO beginning three 
days post tumor injection (Fig 5.1). Hemorrhagic ascites fluid consistently develops 
at approximately 7-8 weeks post p53-/- ID8 injection (44). 
 
Cellular ascites collected from these mice, was further analyzed to characterize 
the mixed population of cells surrounding the disseminated tumor cells. Solid 
tumors were not harvested or analyzed. Ascites was collected, filtered, incubated 
in ACK buffer (Quality Biological) to lyse red blood cells, and washed. Cells were 
blocked with FcR Blocking Reagent (Miltenyi Biotec 130-092-575) and stained for 
cell-surface markers including Live/Dead (eBioscience 65-0865-14), CD45 (BD 
Biosciences 563891), F4/80 (BioLegend 123113), CD11b (BioLegend 101222), 
MHC II (isotype control 400627; BioLegend 107619), CD206 (BioLegend 141708), 
CD11c (BD Biosciences 564079), Ly6C (BD Biosciences 562728), and Ly6G (BD 
Biosciences 563005). Flow cytometry acquisition was performed on an LSR II 
cytometer (BD Biosciences), and data were analyzed using FlowJo software 
version 10.2. 
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For the 2208L breast cancer model, tumor tissue (2mm) is inserted into the 
mammary fat pad of 6-8 week old immunocompetent BALB/c wildtype mice. Breast 
tumor measurements are obtained once weekly and tumors were harvested at pre-
determined time points.  Mice were treated IP with AZA (0.5 mg/kg) or saline 
vehicle, DFMO (2% in water), or combination AZA and DFMO beginning three 
days post tumor implant.  
5.3 Results 
5.3.1  AZA+DFMO in p53-/- ovarian cancer model 
Mice treated with single agent AZA have a slight benefit in survival (median 
survival 67.5 days) compared to untreated mice who have a median survival of 60 
days in this p53-/- ID8 model (Fig. 5.2). Interestingly, there is a significant 
difference between treatment with single agent DFMO in this model versus single 
agent AZA, as DFMO alone dramatically increases survival in these mice to a 
median of 85.5 days. It remains true however that mice treated with combination 
therapy exhibit the largest increase in overall survival with a median survival of 91 
days (Fig. 5.2).   
Myeloid immune cell populations were next examined to determine whether 
combination AZA+DFMO had similar actions on immunosuppressive cells in this 
p53-/- HGSOC model. MDSCs are suppressive immune cells often present in the 
tumor microenvironment, high levels of which are associated with a poor prognosis 
in ovarian cancer, other solid tumors and metastatic disease (10). No significant 
decrease in non-lymphocyte or MDSC populations (both monocyte derived and 
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granulocyte derived) was observed after treatment with AZA and DFMO (Fig 5.3 – 
5.5). Interestingly, total macrophage populations were also not affected by 
treatment and it appears that single agent AZA treatment may trend toward 
increased macrophages at this time point in the hemorrhagic ascites fluid (Fig 5.6). 
It is possible that the immune cell populations in the hemorrhagic ascites fluid may 
not mimic the tumor microenvironment of the solid tumor in this model. Future 
experiments should include immunohistochemistry of the solid tumors isolated 
from mice to determine what immune cells are physically infiltrating the tumor. 
Assessment of only total macrophage populations in the tumor 
microenvironment is not sufficient to gain an accurate view of the distribution and 
behavior of macrophage in and around solid tumors. Although AZA treatment 
appears to increase total macrophages in the hemorrhagic ascites fluid, perhaps 
this is due to recruitment of M1 anti-tumorigenic macrophages, rather than an 
increase in M2 immunosuppressive macrophages (36). Therefore we next 
examined within these total macrophage populations, whether they were more 
representative of an M1 macrophage (CD206- MHC II+) or an M2 macrophage 
(CD206+ MHC II-). Mice treated with single agent DFMO demonstrated an 
increase in the population of M1 macrophages in the hemorrhagic ascites, paired 
with a dramatic decrease in M2 macrophages (Fig 5.7, 5.8). Treatment with single 
agent AZA and combination AZA+DFMO however, led to no significant changes 
in either M1 or M2 macrophages (Fig 5.7, 5.8).  
Another important myeloid cell capable of activating T cells and increasing an 
immune response are dendritic cells, which we also looked at in the tumor 
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microenvironment of these p53-/- mice. No significant changes were observed in 
dendritic cell populations, although single agent AZA did trend toward an increase 
(Fig 5.9). These data are intriguing because in regards to survival, the AZA+DFMO 
treated mice did have the longest overall median survival, yet they do not appear 
to have the changes in macrophage polarization observed in the VDID8 model 
(Chapter 2). Again, immune cells surrounding and infiltrating the solid tumors in 
this p53-/- ID8 model may be more important, and should be investigated in future 







Figure 5.1: Tumor cell injection and treatment schematic. Mice were injected IP 
with 5,000,000   p53-/- ID8 cells and treated with 0.5 mg/kg of AZA/saline IP 5 days 
a week, every other week. 2% DFMO was provided in water bottles. Mice were 
treated throughout the duration of the experiment. Upon 25-30% weight gain, 





Figure 5.2: Survival curve (median survival in days); n = 10 mice per group. 
Significance determined using log-rank Mantel-Cox test. 
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Figure 5.3: Total non-lymphocyte cells in the tumor microenvironment, as a 
percentage of total cells collected from ascites fluid. No changes with treatment 




Figure 5.4: Total monocyte derived MDSCs in the tumor microenvironment, as a 
percentage of total cells. No changes with treatment were observed, and overall 




Figure 5.5: Total granulocyte derived MDSCs in the tumor microenvironment, as 
a percentage of total cells. No changes with treatment were observed, and overall 




Figure 5.6: Total macrophages in the tumor microenvironment, as a percentage 
of total cells. No significant changes were observed with treatment, although it 
appears that single agent AZA treatment trends toward increased macrophages in 




Figure 5.7: M1 macrophages (CD206- MHC II+) in the tumor microenvironment, 




Figure 5.8: M2 macrophages (CD206+ MHC II-) in the tumor microenvironment, 




Figure 5.9: Total dendritic cells in the tumor microenvironment, shown as a 
percentage of total cells. Single agent AZA treatment trends toward an increase in 




5.3.2  DFMO alone reduces tumor burden in 2208L breast model 
Combination AZA+DFMO treated mice in the 2208L breast tumor model had 
increased survival and decreased tumor burden as measured in weeks 3 through 
6 post tumor implant surgery (Fig 5.10 – 5.14). Interestingly, this benefit in survival 
and tumor burden appears to again be driven by DFMO. Single agent AZA 
treatment had no impact on tumor size in these mice, and no benefit in survival 
(Fig 5.10 – 5.14). 
Myeloid immune cell populations were next examined to determine whether 
combination AZA+DFMO had similar actions on immunosuppressive cells in this 
2208L breast cancer model. No significant changes to total MDSC or macrophage 
populations were observed with treatment (n=3 mice per group), except perhaps 
a trend toward an increase in total macrophages with DFMO treatment (Fig 5.15 
and 5.16). 
It is essential to investigate macrophage populations further because 
depending on the suite of genes expressed, a macrophage in the tumor 
microenvironment could be either pro- or anti-tumorigenic. In this experiment, we 
were unable to consider the surface protein CD206 which is upregulated on M2 
polarization macrophages, and instead examined M1 surface markers including 
MHC II and CD86. The surface molecule CD86 is upregulated on activated 
macrophages and dendritic cells, and is known as a co-stimulatory molecule that 
interacts with CD28 on T cells, aiding in their activation and proliferation (36). 
Therefore macrophages positive for both MHC II and CD86 would be considered 
M1 macrophages, capable of T cell activation (36). Combination AZA+DFMO 
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resulted in a trending increase in M1 macrophages, however changes were not 
significant possibly due to low sample number (Fig 5.17). 
Another myeloid derived cell capable of T cell activation, and in fact the most 
adept cell type at T cell activation, is the dendritic cell (54). Dendritic cells are 
phagocytic cells that regularly uptake exogenous antigen from their surrounding 
environment and in the presence of an infection, will help tailor the immune 
response by secreting certain cytokines (54). They will additionally upregulate 
surface expression of MHC II and the co-stimulatory molecules CD80 and CD86 
to enable them to present antigen to nearby T cells, thereby activating them (54). 
The established anti-viral, interferon response induced by AZA treatment should 
in fact increase activation of dendritic cells, therefore exploring their role in the 
tumor microenvironment could be important (14,17,18). Firstly, we assessed 
dendritic cell populations overall in these breast tumors, both as a percentage of 
CD45+ immune cells and as a percentage of total cells and found that combination 
AZA+DFMO may increase dendritic cell populations overall in the tumor 
microenvironment (Fig 5.18 and 5.19). Low sample numbers did not provide 
enough power for statistical significance; however the data overall are intriguing. 
Although AZA did not impact total dendritic cell numbers, it may potentially 
impact the activation of dendritic cells, which can be assessed through surface 
expression of the co-stimulatory signaling proteins CD80 and CD86 (54). In fact, 
even with low sample numbers, we were able to demonstrate a significant increase 
in activated and mature dendritic cells with AZA treatment, which is in line with the 
interferon response launched by this drug treatment (Fig 5.20) (14,17,18). 
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Importantly however, AZA treatment did not prove beneficial to these mice in terms 
of tumor size or burden, or overall survival (Fig 5.10 – 5.14). It would appear that 
activating an immune response against this tumor via AZA treatment does not 
have a sufficient anti-tumorigenic impact, perhaps due to the high populations of 
myeloid derived suppressor cells and other immunosuppressive cells in the tumor 
microenvironment. DFMO treatment, which is known to impact these cell 
populations, has a greater impact on survival and tumor burden in these mice 
(24,26).  
In order for activated dendritic cells to activate T cell populations, they require 
a favorable microenvironment without high populations of immunosuppressive 
cells; however even in the combination AZA+DFMO, the addition of AZA did not 
provide further benefit. There could be other mechanisms at play preventing 
dendritic cells from activating T cells, or preventing T cells from infiltrating the tumor 
site. Immunohistochemistry experiments in the future could provide more insights 







Figure 5.10: Survival curve (median survival in days); n = 4. Significance 
determined using log-rank Mantel-Cox test. 
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Figure 5.11: Tumor size as measured once weekly in 2208L mice (week 3 post 




Figure 5.12: Tumor size as measured once weekly in 2208L mice (week 4 post 
tumor implant). Both untreated and AZA treated mice begin to have increased 
tumor volume. n=10. 
109 
 
Figure 5.13: Tumor size as measured once weekly in 2208L mice (week 5 post 
tumor implant). Treatment with DFMO as both a single agent and in combination 




Figure 5.14: Tumor size as measured once weekly in 2208L mice (week 6 post 
tumor implant). Treatment with DFMO as both a single agent and in combination 
with AZA maintains low tumor volumes. n=10. 
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Figure 5.15: Total MDSCs in the tumor microenvironment, as a percentage of total 




Figure 5.16: Total macrophages in the tumor microenvironment, as a percentage 
of total cells. No significant changes were observed with treatment, although single 
agent DFMO is trending toward an increase in macrophages, the opposite of what 




Figure 5.17: M1 macrophages in the tumor microenvironment of the breast 2208L 
model, shown as a percentage of macrophages. DFMO treatment trends toward 
an increase in M1 macrophages. n=3. 
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Figure 5.18: Dendritic cells in the tumor microenvironment of the 2208L breast 
cancer model, shown as a percentage of CD45+ immune cells. No significant 




Figure 5.19: Dendritic cells in the tumor microenvironment of the 2208L breast 
cancer model, shown as a percentage of total cells. No significant changes were 
observed with treatment. n=3. 
116 
 
Figure 5.20: Mature or activated dendritic cells in the tumor microenvironment of 
the 2208L breast cancer model, shown as a percentage of dendritic cells. AZA 
treatment increases activation of these cells. n=3. 
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5.3.3  DFMO activates GATA6+ peritoneal macrophages in ovarian tumors 
An additional factor to consider when analyzing macrophage populations in the 
tumor microenvironment is whether these macrophages are tissue resident cells 
or recruited cells from secondary lymphoid tissue. It is now well understood that 
certain macrophage populations are seeded out into respective tissue sites during 
embryogenesis (55). These macrophage subsets include Kupffer cells, 
Langerhans cells, and alveolar macrophages in liver, skin, and lung tissue 
respectively (55). In the peritoneum where the tumor microenvironment exists for 
our VDID8 ovarian cancer mouse model, the tissue resident macrophage 
population are peritoneal macrophages (53,55). These peritoneal macrophages 
are known to depend on the transcription factor GATA6 for their differentiation and 
survival (56,57). Nuclear flow cytometry staining for transcription factors is the 
most common way to identify T regulatory cells, via expression of the transcription 
factor Foxp3; therefore identifying macrophages positive for the factor GATA6 will 
define whether a macrophage is a tissue resident cell or a recruited cell from 
secondary lymphoid tissue (58,59). 
Total macrophages were found to be decreased with DFMO alone and 
AZA+DFMO during this third ascites drain (Fig 5.21). For logistical reasons, the 
third drain of ascites fluid at week 6 was analyzed during this experiment. Of these 
total macrophages, on average roughly 50 percent of the cells were positive for 
GATA6 and are considered to be peritoneal macrophages, although the data does 
have wide variation (Fig 5.22). Some mice have a very high percentage of 
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peritoneal macrophages and others have a lower percentage, which is the case 
for every treatment arm (Fig 5.22). 
Next, the sub-classification of macrophage was examined to see whether 
peritoneal macrophages had a classically polarized M1 macrophage phenotype or 
an alternative polarization of M2. As has been observed several times in prior 
experiments, treatment with DFMO, AZA, and especially AZA+DFMO caused an 
increase in M1 macrophages in the tumor microenvironment, and a decrease in 
M2 macrophages (Fig 5.23, 5.24). Again, this data is during the third draining of 
ascites fluid and therefore the increase in M1 macrophages is not quite as high as 
that seen in the second drain in Figure 4.6, likely due to the increase in tumor 
burden at this time (Fig 5.23). Alternatively polarized M2 macrophages remain very 
low in mice treated with DFMO, but have begun to slightly rise in AZA treated mice 
(Fig 5.24). 
To answer the question of whether peritoneal macrophages were regulated by 
treatment, cells positive for all three factors (F4\80, CD11b, and GATA6) were 
further analyzed for markers related to M1 and M2 macrophages (MHC II and 
CD206). M1-like peritoneal macrophages increased with DFMO treatment, 
whether it was DFMO alone or in combination with AZA (Fig 5.25), and M2-like 
peritoneal macrophages decreased with DFMO treatment (Fig 5.26). Interestingly, 
it does not appear that AZA has a significant impact on this cell population, as M1-
like peritoneal macrophages do not increase with AZA treatment compared to 
mock treated mice, and M2-like peritoneal macrophages only slightly decrease 
(Fig 5.25, 5.26) 
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These data are intriguing because AZA treatment does increase M1 
macrophages in this VDID8 model, as seen in Figure 4.6 and again in Figure 5.23, 
similar to the increase seen in DFMO alone; however, AZA treatment does not 
increase the tissue resident macrophages that are positive for M1-like features (Fig 
5.25). These data therefore suggest that AZA treatment is increasing M1 
macrophages through another mechanism—namely through recruitment of 
macrophages from secondary lymphoid tissue. DFMO in contrast, is able to impact 
macrophages directly at the tissue site (Fig 5.25, 5.26). The differing impacts these 
drugs have on tissue resident versus recruited macrophages could help to explain 
the mechanism for why this drug combination works synergistically compared to 
the single agents. DFMO is able to drive tissue resident macrophages toward a 
classic polarization that is anti-tumorigenic, while AZA activates an interferon 





Figure 5.21: Total macrophages in the tumor microenvironment of the VDID8 




Figure 5.22: Peritoneal macrophages in the tumor microenvironment of the VDID8 
model shown as a percentage of macrophages. On average, roughly 50 percent 
of the macrophages are tissue resident peritoneal macrophages. 
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Figure 5.23: Total M1 macrophages as a percentage of cells in DFMO, AZA, and 
AZA+DFMO treated mice compared to mock mice. All treatment arms show an 
increase in M1 macrophages, though DFMO alone shows the highest increase 




Figure 5.24: Total M2 macrophages as a percentage of cells in DFMO, AZA, and 
AZA+DFMO treated mice compared to mock mice. Combination treated mice have 




Figure 5.25: Peritoneal macrophages exhibiting an M1-like phenotype positive for 
MHC II and negative for CD206, shown as a percentage of peritoneal 




Figure 5.26: Peritoneal macrophages exhibiting an M2-like phenotype negative 
for MHC II and positive for CD206, shown as a percentage of peritoneal 
macrophages. Mice treated with DFMO demonstrate a decrease in this population. 
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5.4 Discussion 
The testing of our novel drug combination of AZA and DFMO in two additional 
solid tumor models has shown that combination AZA+DFMO  provides the greatest 
survival benefit in both the p53-/- solid tumor ID8 ovarian model and the 2208L 
breast cancer model (Fig 5.2, 5.10). Interestingly however, both of these solid 
tumor models exhibited significant benefits in terms of survival and tumor burden 
with DFMO alone over single agent AZA (Fig 5.2, 5.10-5.14). Furthermore, when 
tissue resident macrophage populations were analyzed in respect to this drug 
combination in the VDID8 model, it was discovered that DFMO alone had a 
significant impact on the tissue resident macrophage populations (Fig 5.25, 5.26). 
It could therefore be possible that DFMO has a greater benefit in solid tumor 
models due to its ability to act directly at the tumor site on tissue resident 
macrophages. With AZA’s proposed mechanism of action through a system wide 
interferon/anti-viral response, perhaps the time required to launch this response 
works against AZA in the solid tumor model. Importantly, the VDID8 ovarian cancer 
model is an overexpression model of VEGF which produces high volumes of 
hemorrhagic ascites and increased vasculature. In this model, AZA alone provides 
a survival benefit very similar to single agent DFMO, perhaps because the 
increased vasculature allows rapid recruitment of immune cells from the secondary 
lymphoid tissues.   
M1 macrophages were generally increased with treatment in these solid tumors 
(Fig 5.17, 5.7), though not as dramatically as was seen in the VDID8 model. In the 
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case of the p53-/- model, the macrophages analyzed are those isolated from 
hemorrhagic ascites fluid, and therefore may contain a significant population of 
peritoneal macrophages. It therefore is logical that DFMO treatment is able to 
impact these macrophages (Fig 5.7, 5.8) while AZA treatment appears to have 
less of an impact. Data from the breast model does represent immune cells in the 
physical solid tumor, and there appears to be a modest increase in M1 
macrophages with all treatment arms (Fig 5.17). AZA treatment was also found to 
increase activation and maturation of dendritic cells in both solid tumor models (Fig 
5.9, 5.20). These data are also in line with AZA’s interferon response, however 
again, it appears that this increase in activated dendritic cells was not sufficient to 
elicit a major benefit to survival or tumor burden (Fig 5.2, 5.10-5.14). Overall, 
combination AZA+DFMO had a significant benefit to survival in both the p53-/- 
ovarian ID8 model and 2208L breast model, but the impacts on immune cell 
populations and their contribution to this survival benefit are less clear. 
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Conclusions and Future Directions 
6.1 Summary 
Combination epigenetic and polyamine reducing therapy is an effective 
treatment strategy for ovarian cancer in immunocompetent mice, prolonging 
survival and decreasing tumor burden significantly. This treatment regimen 
represents the first combination of these two drug therapies in mice, and the first 
use of DFMO in an immunocompetent mouse model for ovarian cancer (60). 
Treatment with AZA alone led to an increase in IFNγ+ NK cells, CD4+ T cells, and 
CD8+ T cells, as has been demonstrated before (13,17,18). Signaling of IFNγ via 
its receptor IFNGR1 on tumor cells can lead to increased expression of PD-L1 on 
tumor cells, thereby making this increase in IFNγ an attractive candidate for α-PD-
1 therapy. However, α-PD-1 therapy had no significant impact on survival in this 
model when added to the combination AZA and DFMO.  These results are in 
contrast to previous studies using AZA and HDACi where the addition of α-PD-1 
produced a significant therapeutic response (17). Histone acetylation is essential 
for transcription of IFNγ, therefore the use of an HDACi may explain the 
sensitization to α-PD-1 therapy previously seen, as increasing histone acetylation 
even further increased IFNγ levels in lymphocytes (61).  
 Analysis of the tumor microenvironment after the combination treatment 
with AZA and DFMO indicated that the impacts on macrophage polarization are 
critically important in this model. AZA treatment has been shown to decrease 
macrophages in the tumor microenvironment, though previously no distinction was 
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made as to the polarization status of these macrophages (17,18). As the 
understanding of macrophages deepens, research has discovered that these cells 
once thought of as permanent, differentiated cells, are in fact quite plastic and able 
to respond to multiple signals including cytokines and chemokines that direct their 
behavior and alter their phenotype. Classically polarized M1 macrophages, 
induced by cytokines such as IFNγ and IL-12, upregulate expression of MHC II 
and can have tumoricidal functions. M1 macrophages metabolize arginine via 
iNOS to nitric oxide (NO), creating an oxidizing environment that is damaging to 
surrounding cells. DFMO treatment has been found to potentiate NO production in 
LPS-stimulated macrophages in vitro (40). Additionally, DFMO, via product 
inhibition through the increase in ODC substrate, ornithine, inhibits the enzyme 
arginase I, which is essential for function of alternatively polarized M2 
macrophages (22,30). Inhibition of arginase I could lead to increased amounts of 
its substrate arginine, potentially providing more of the metabolite for use by M1 
macrophages and iNOS (30,36). Treatment with DFMO may therefore increase 
M1 macrophages by making more of its essential metabolite arginine available, 
while AZA may help increase M1 macrophages via its interferon response and 
production of IFNγ, a cytokine which drives M1 polarization (14,17,18,36). 
 Depletion of macrophages in the tumor microenvironment using a CSF1R 
antibody significantly diminished the efficacy of combination AZA and DFMO, and 
decreased the levels of M1 macrophages. Tumor burden recurred more rapidly 
and survival was diminished in mice with fewer macrophages, suggesting that 
these M1 macrophages could have a tumoricidal role in ovarian tumors. 
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Importantly, the CSF1R antibody depletes peritoneal macrophages, and has not 
been shown to reduce recruited macrophages from secondary lymphoid tissue 
(53). Experiments assessing GATA6 positive macrophages in the VDID8 ovarian 
model showed that DFMO alone had a significant impact on the tissue resident 
macrophage populations (Fig 5.24, 5.25). It could therefore be possible that 
depleting the peritoneal macrophages with the CSF1R antibody prevented 
DFMO’s action on the tissue resident macrophages, resulting in fewer M1 
macrophages in the tumor microenvironment (Fig 4.17). AZA treatment in this 
CSF1R antibody block experiment could still have been able to activate an 
interferon response and recruit M1 macrophages from the periphery, but perhaps 
this effect was not enough. In fact, the survival curve for mice receiving CSF1R 
antibody in combination with AZA+DFMO looks similar to that of a mouse receiving 
single agent AZA (Fig 4.16, 3.4). These data are in line with DFMO’s proposed 
action on tissue resident macrophages—by depleting these macrophages, DFMO 
is less able to alter macrophage polarization, and there is a resultant decreased 
survival.  
6.2 Future Directions 
This work represents the first combination of these two distinct treatment 
strategies of epigenetic therapy and polyamine reducing therapy in any cancer. 
The impact of AZA and DFMO on macrophages in the tumor microenvironment 
may not be specific to ovarian cancer, and could therefore possibly translate to 
other macrophage-rich tumors. Furthermore, the use of two well-tolerated and 
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clinically approved drugs offers potential to test a third drug in combination to 
further prolong survival. Examples of additional drug combinations could include 
polyamine transport inhibitors, additional epigenetic therapies such as HDACis, or 
possibly therapeutic antibodies that deplete M2 macrophages such as α-IL-10R. 
Exploration of additional drugs that potentiate M1 macrophages is important, as 
these tumoricidal cells have potential to decrease tumor burden and help activate 
the immune system against cancer.  
In addition to exploring the potential for additional drugs in this combination 
AZA+DFMO treatment regimen, the role of NK cells in the treatment response 
could also be further investigated. Combination AZA and DFMO led to a 
pronounced increase in NK cells positive for IFNγ, significantly more than that of 
either single agent alone (Fig 3.17). One possibility is that these high levels of IFNγ 
are precisely what helps to promote the polarization of M1 macrophages, as this 
cytokine is known to stimulate M1 polarization (36). The potential that these NK 
cells are playing an additional anti-tumorcidal role however cannot be ruled out. 
Depletion experiments against NK cells could provide some insight into this 
question. 
Another unanswered question that could potentially be investigated would be 
the precise role of M1 macrophages against the tumor. These macrophages could 
be directly tumoricidal via nitric oxide pathways, or they could be activating T cells 
and in fact it is the CD8+ T cells and NK cells that are primarily responsible for 
cytotoxicity. Furthermore, how exactly the tumor cell is impacted by these drugs is 
still an unanswered question—is the immune system actively killing tumor cells or 
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is it halted growth? Cell cycle experiments suggest that apoptosis is not a primary 
mechanism, nor is halted growth, so perhaps immunological forms of cell death 
are at play including necroptosis (programmed necrosis), pyroptosis (inflammatory 
cell death), or simple necrosis (sudden cell death due to injury). The mechanism 
of tumor cell death is an interesting question that could still be explored in this 
model.  
Lastly, experiments exploring the role of tissue resident versus recruited 
macrophages by looking at levels of the transcription factor GATA6 suggested an 
important role for DFMO on peritoneal macrophages (Fig. 6.1). Additionally, the 
CSF1R depletion experiment which depletes tissue resident peritoneal 
macrophages but not necessarily recruited macrophages from the bone marrow 
suggested that the combined impact (DFMO on tissue resident, and AZA on 
recruited macrophages) is a major factor to the efficacy of this combination 
therapy. To truly discover the impact of recruited macrophages, the same 
AZA+DFMO experiment could be repeated in a mouse knockout model for CCR2, 
the essential chemokine receptor that recruits macrophages from the bone marrow 
and secondary lymphoid tissue (62). If single agent DFMO performs similarly in 
this CCR2 knockout, one could make the reasonable conclusion that its impacts 
are primarily on tissue resident macrophages. It would also be anticipated that 
single agent AZA could have less of an impact if the recruited M1 macrophages 
are essential to its mechanism. Alternatively, AZA may still have a benefit if the 




Figure 6.1: Schematic demonstrating hypothesis that DFMO treatment works at 
the tumor tissue site, and is able to promote tissue resident macrophages toward 
M1 polarization. In contrast AZA treatment, which elicits a type I interferon 
response, leads to recruitment of M1 macrophages from secondary lymphoid 
tissue. The two drugs combined thus lead to the largest increase in M1 
macrophages in the tumor microenvironment, and the strongest benefit in survival. 
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Regulation, Cellular Structure and Dynamics, and Molecular Biology and 
Genomics.  
 Taught a 1-hour, once-weekly class addressing challenging concepts. 
Cornell University, Teaching Assistant, Biochemistry Sep 2008 – Dec 2008 
Cornell University, Academic Excellence Workshop Facilitator 
Calculus I and Calculus II Aug 2006 – Dec 2008 
ACADEMIC SERVICE           
Student Representative 
Cellular and Molecular Medicine Student Senate        June 2018 – June 2019 
PROFESSIONAL AFFILIATIONS         
American Association for Cancer Research, Associate Member 
HONORS           
Honorable Mention in Translational Research 
 SKCCC Fellow Research Day, June 2018. 







ENGINEERING EXPERIENCE          
DePuy Synthes, Raynham, MA Apr 2014 – Aug 2015 
Regulatory Affairs, Spine Medical Devices 
 Data management for Unique Device Identification (UDI) spine regulatory 
database to ensure compliance with new Federal Drug Administration (FDA) 
regulations.  
 Verify initial records and maintain compliance of the regulatory database. 
 
E.A. Engineering, Science, and Technology, Warwick, RI  Aug 2009 – Apr 2014 
Engineer  
 Excelled in Data Management role for large-scale air sampling project. Analyzed 
data trends and conducted review of data anomalies. Compiled all verified data 
and presented results in an effective and efficient manner. 
 Prepared conceptual, preliminary, and final designs for nature-like fishway 
bypass channels. 
 Conducted two major developmental analyses to determine economic viability of 
multi-dam and power generating facilities for Federal Energy Regulatory 
Commission. 
 
 
